专利摘要:
NEUTRALIZING ANTIBODIES OF THE PROLACTIN RECEPTOR AND ITS THERAPEUTIC USE. The present invention relates to the neutralizing antibody of the 006-H08 prolactin receptor, as well as mature forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostatic hyperplasia, fibroids, hyper and normoprolactinemic hair loss, and co-treatment in combined hormone therapy to inhibit proliferation of mammary epithelial cells. The antibodies of the invention block prolactin receptor-mediated signaling.
公开号:BR112012015852B1
申请号:R112012015852-0
申请日:2010-11-18
公开日:2020-12-29
发明作者:Christiane Otto;Siegmund Wolf;Christoph Freiberg;Axel Harrenga;Simone Greven;Mark Trautwein;Sandra Bruder;Andrea Eicker;Andreas Wilmen
申请人:Bayer Intellectual Property Gmbh;
IPC主号:
专利说明:

[001] The present invention targets the 006-H08 prolactin receptor antibody and provides recombinant antigen binding regions and antibodies and functional fragments containing such antigen binding regions that specifically bind and neutralize the prolactin receptor, acid sequences nucleic acid encoding the previous antibodies, vectors containing them, pharmaceutical compositions containing them and their use in the treatment or prevention of benign diseases and indications that benefit from inhibition of prolactin receptor-mediated signaling such as endometriosis, adenomyosis, non-female contraception -hormonal, benign breast disease, mastalgia, inhibition of lactation, benign prostatic hyperplasia, fibroids as well as hyper and normoprolactinemic hair loss, and co-treatment in combined hormonal therapy to inhibit proliferation of mammary epithelial cells.
[002] There is an unmet medical need for the treatment of various benign diseases and indications such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease, mastalgia, lactation inhibition, benign prostatic hyperplasia, fibroids, hair loss hyper and normoprolactinemic, and prevention of proliferation of breast epithelial cells in combination hormone therapy (ie, estrogen plus progestin).
[003] Prolactin (PRL) is a polypeptide hormone composed of 199 amino acids. PRL belongs to the family of polypeptide hormones - growth hormone (GH), placental lactogen (PL) - and is synthesized in the pituitary lactotrophic cells and in various extrapituitary tissues such as lymphocytes, mammary epithelial cells, the myometrium, and the prostate. Two different promoters regulate the synthesis of pituitary and extrapituitary PRL (BioEssays 28: 1051-1055, 2006).
[004] PRL binds to the PRL receptor (PRLR), a simple transmembrane receptor that belongs to the class 1 cytokine receptor superfamily (Endocrine Reviews 19: 225-268, 1998). The PRLR exists in three different isoforms, the short, the long, and the intermediate form, which can be distinguished by the length of their cytoplasmic tails. Under ligand binding, a sequential process leads to activation of the PRLR. PRL interacts through its binding site 1 with a molecule of the PRLR and then attracts through its binding site 2 a second receptor molecule leading to an active dimer of the PRLRs. Dimerization of PRLR leads to the predominant activation of the JAK / STAT (Janus Kinase / Signal Transducers and Activators of Transcription) pathway. Under dimerization of the receptor, JAKs (predominantly JAK2) associated with the receptor, transfosphorylate and activate with each other. In addition, PRLR is also phosphorylated and can bind to the SH2 domain containing proteins such as STATs. Receptor-bound STATs are subsequently phosphorylated, dissociate from the receptor and move to the nucleus where they stimulate the transcription of target genes. In addition, activation of the Ras-Raf-MAPK pathway and activation of cytoplasmic src kinase by PRLRs have been described (for review Endocrine Reviews 19: 225-268, 1998).
[005] PRLR-mediated signaling plays a role in a variety of processes such as mammary gland development, lactation, reproduction, mammary and prostate tumor growth, autoimmune diseases, general growth and metabolism, and immunomodulation (Endocrine Reviews 19: 225- 268, 1998; Annu. Rev. Physiol. 64: 47-67, 2002).
[006] Currently, complete interference with PRLR-mediated signaling is not possible. The only way to interfere with PRLR-mediated signaling is to inhibit secretion of pituitary PRL using bromocriptine and other dopamine 2 receptor agonists (Nature Clinical Practice Endocrinology and Metabolism 2 (10): 571-581, 2006) . These agents, however, do not supply the extrapituitary PRL synthesis, which can successfully compensate for the inhibition of pituitary PRL synthesis leading to almost intact PRLR-mediated signaling (Endocrine Reviews 19: 225- 268,1998). Therefore, it is not surprising that type 2 dopamine receptor agonists were not beneficial in patients suffering from breast cancer or autoimmune diseases, such as systemic lupus or rheumatoid arthritis (Breast Cancer Res. 14: 289-29, 1989; Lupus 7: 414-419, 1998) although prolactin has been implicated in these diseases. Synthesis of local prolactin in breast cancer cells or lymphocytes, which plays a pivotal role in breast carcinoma or autoimmune diseases, respectively, has not been blocked by dopamine receptor agonists.
[007] Despite the aforementioned attempts to provide means for the treatment or prevention of benign diseases and indications such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper and normoprolactinemic hair loss, and co-treatment in combined hormonal therapy for the prevention of breast epithelial cell proliferation, no compound is yet available to satisfy that need. It is, therefore, an objective of the present invention, to solve that problem by providing compounds that are therapeutic for these benign diseases and indications.
[008] Now, new antibodies have been identified that are specific and have a high affinity for PRLR and thus neutralize PRLR-mediated signaling and that can deliver a therapeutic benefit to the subject.
[009] Blocking PRLR activation by neutralizing PRLR antibodies leads to complete inhibition of PRLR-mediated signaling. In contrast, dopamine receptor agonists can only interfere with enhanced PRLR-mediated signaling in response to increased secretion of pituitary prolactin, but not with enhanced PRLR-mediated signaling due to an activating PRLR mutation or due to locally elevated production prolactin.
[0010] Therefore, the problem is solved by the provision of the 006-H08 antibody, and antigen binding fragments thereof, or its variants for the treatment of the benign diseases and indications mentioned above, which bind to the PRLR with high affinity, efficiently neutralize signaling mediated by PRLR, and which are preferably cross-reactive with PRLR from other species such as Macacca mulatta and Macacca fascicularis, Mus musculus or Rattus norvegicus.
[0011] Some PRLR antibodies have already been described in patent application WO2008 / 022295 (Novartis) and in US patent 7,422,899 (Biogen). The present invention is based on the discovery of new antibodies that are specific and have a high affinity for PRLR and thus neutralize PRLR-mediated signaling and that can release a therapeutic benefit to the subject (new antibody sequences are as in SEQ ID NO : 34, 40, 46, and 52). The antibodies of the invention, which can be human or humanized or chimeric or engineered humans, can be used in many contexts that are more fully described here.
[0012] Therefore an object of the present invention is an antibody or antigen binding fragment, whereby said antibody antagonizes prolactin receptor-mediated signaling.
[0013] The new antibodies "002-H06", "002-H08", "006-H07", "001- E06", "005-C04" are the subject of the corresponding patent applications.
[0014] In vivo characterization of these antibodies in murine models of disease is only possible with an antibody exhibiting reactivity to the murine prolactin receptor. Only the 005-C04 antibody, which is disclosed in a corresponding patent application, shows sufficient cross-reactivity to the murine prolactin receptor and is therefore the only antibody that can be used in murine in vivo models. The results obtained with this antibody therefore prove to be a substitute for general efficacy for all other prolactin receptor neutralizing antibodies which are disclosed in the corresponding patent applications in the analyzed disease models.
[0015] Antibodies have been characterized in various cellular systems to determine their specificity for species and their potency as well as effectiveness in different reading paradigms that deal with PRLR-mediated signaling inactivation (see Examples 5 - 10). Proliferation assays were performed with rat Nb2-11 cells (Example 6, Figure 6) or Ba / F cells or stably transfected with human PRLR (Example 5, Figure 5) or murine PRLR (Example 10, Figure 10). While the Novartis XHA 06.983 antibody did not show activity in the rat and murine PRLR, the Novartis XHA06.642 antibody showed activity in the rat PRLR but not in the murine PRLR. XHA 06.642 inhibited human PRLR-mediated signaling (Example 5, 7, 8). The new antibody of the present invention 006-H08 showed the highest potency with respect to inhibition of proliferation of Ba / F cells stably transfected with human PRLR (Example 5, Figure 5). The new antibody 005-C04 from a corresponding patent application was the only antibody that showed cross-reactivity in the murine (Example 10, 9) and human (Examples 5, 7, 8) PRLR. In contrast to the Novartis XHA06.642 antibody, the new 005-C04 antibody is therefore suitable for testing the inhibition of PRLR-mediated signaling in murine models. All other antibodies described in this patent application or the corresponding patent applications are specific to human PRLR. In addition to cell proliferation assays (Examples 5, 6, 10), luciferase reporter assays were performed using HEK293 cells stably transfected with either human (Example 8) or murine (Example 9) PRLR and transiently transfected with a reporter gene from luciferase under the control of LHRE's (lactogenic elements of hormonal response). Using these systems the inability of the Novartis XHA06.642 antibody to efficiently block murine PRLR-mediated signaling was evident again (Example 9). In contrast, the new antibody 005-C04 (corresponding patent application) blocked the activation of the luciferase reporter gene by the murine PRLR (Example 9). Phosphorylation of STAT5 in human T47D cells was used as an additional reading to analyze the inhibitory activity of antibodies in human PRLR (Example 7, Figure 7). As expected, the non-specific antibodies were inactive in all the experimental paradigms analyzed.
[0016] The present invention relates to methods for inhibiting the growth of PRLR-positive cells and the progression of the benign diseases and indications mentioned above by providing anti-PRLR antibodies. Provided are human monoclonal antibodies, antigen binding fragments thereof, and variants of the antibodies and fragments that specifically bind to the extracellular domain (ECD) of PRLR (SEQ ID NO: 70) or human polymorphic variants of SEQ ID NO: 70 such as the I146L and I76V variants being described in PNAS 105 (38), 14533, 2008, and J. Clin. Endocrinol. Metab. 95 (1), 271, 2010.
[0017] Another objective of the present invention is an antibody that binds epitopes of the extracellular domain of the prolactin receptor and human polymorphic variants thereof, whereby the amino acid sequence of the extracellular domain of the prolactin receptor corresponds to SEQ ID NO: 70, and the nucleic acid sequence corresponds to SEQ ID NO: 71.
[0018] The antibodies, antigen binding fragments, and variants of the antibodies and fragments of the invention are comprised of a light variable chain region and a heavy variable chain region. Variants of the antibodies or antigen binding fragments contemplated in the invention are molecules in which the antibody binding activity or antibody antigen binding fragment to PRLR is maintained (for the sequences see table 5).
[0019] Therefore, an object of the present invention is an antibody or antigen binding fragment, whereby the antibody or antigen binding fragment competes with antibody 006-H08 or defined mature variants thereof. The sequences of the antibodies and their mature variants are described in Table 5.
[0020] In another embodiment, an antibody or antigen binding fragment is revealed, a. whereby the amino acid sequences of the heavy and light variable regions are at least 60%, more preferred 70%, most preferred 80%, or 90%, or even more preferred 95% identical to SEQ ID NO: 34 for the heavy variable chain domain and, identical to SEQ ID NO: 40 for the light variable chain domain, or b. whereby the mature forms of the 006-H08 antibody are the amino acid sequences of the heavy variable and light chain domain at least 60%, more preferred 70%, most preferred 80%, or 90%, or even more preferred 95% identical to this one, or c. whereby the amino acid sequences of the CDRs are at least 60%, most preferred 70%, most preferred 80%, most preferred 90%, or even more preferred 95% identical to SEQ ID NO: 1, 7, and 13 for the heavy chain domain, and SEQ ID NO: 18, 24, and 29 for the light variable chain domain.
[0021] In another embodiment, an antibody or antigen binding fragment comprising the CDRs of the 006-H08 antibody is disclosed, whereby a. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7 and 13 and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, and 29. b. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 78, 24, 90; or c. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 75, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 82, 24, 91; or d. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 82, 24, 29; or e. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 86, 24, 29; or f. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 87, 24, 100; or g. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 87, 24, 92; or h. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 89, 24, 93; or i. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 79, 24, 101; or j. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 76, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 89, 24, 90; or k. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 100; or l. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 97; or m. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 98; or h. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 83, 24, 99; or the. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 96; or p. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 94; or q. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 88, 24, 90; or r. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 74, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 81, 24, 95; or s. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 75, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 29; or t. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 77, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 18, 24, 29; or u. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 80, 24, 29; or V. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 85, 24, 29; or w. the heavy variable chain contains the CDR sequences that correspond to SEQ ID NO: 1, 7, 13, and the light variable chain contains the CDR sequences that correspond to SEQ ID NO: 84, 24, 29.
[0022] In one embodiment, the human 006-H08 antibody, or mature form thereof, is revealed, whereby antibody a. 006-H08 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 46, and an amino acid sequence according to SEQ ID NO: 34, and a light variable domain with a nucleic acid sequence according to SEQ ID NO: 52, and an amino acid sequence according to SEQ ID NO: 40. b. 006-H08-12-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 331, and an amino acid sequence according to SEQ ID NO: 353, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 165, and an amino acid sequence according to SEQ ID NO: 143, c. 006-H08-13-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 332, and an amino acid sequence according to SEQ ID NO: 354, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 166, and an amino acid sequence according to SEQ ID NO: 144, d. 006-H08-13-6-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 333, and an amino acid sequence according to SEQ ID NO: 355, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 167, and an amino acid sequence according to SEQ ID NO: 145, e.g. 006-H08-14-6-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 334, and an amino acid sequence according to SEQ ID NO: 356, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 168, and an amino acid sequence according to SEQ ID NO: 146, f. 006-H08-15-5 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 335, and an amino acid sequence according to SEQ ID NO: 357, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 169, and an amino acid sequence according to SEQ ID NO: 147, g. 006-H08-19-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 336, and an amino acid sequence according to SEQ ID NO: 358, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 170, and an amino acid sequence according to SEQ ID NO: 148, h. 006-H08-29-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 337, and an amino acid sequence according to SEQ ID NO: 359, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 171, and an amino acid sequence according to SEQ ID NO: 149, i. 006-H08-32-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 338, and an amino acid sequence according to SEQ ID NO: 360, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 172, and an amino acid sequence according to SEQ ID NO: 150, j. 006-H08-33-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 339, and an amino acid sequence according to SEQ ID NO: 361, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 173, and an amino acid sequence according to SEQ ID NO: 151, k. 006-H08-33-16-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 340, and an amino acid sequence according to SEQ ID NO: 362, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 174, and an amino acid sequence according to SEQ ID NO: 152, l. 006-H08-35-17-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 341, and an amino acid sequence according to SEQ ID NO: 363, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 175, and an amino acid sequence according to SEQ ID NO: 153, m. 006-H08-35-17-4 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 342, and an amino acid sequence according to SEQ ID NO: 364, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 176, and an amino acid sequence according to SEQ ID NO: 154, h. 006-H08-35-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 343, and an amino acid sequence according to SEQ ID NO: 365, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 177, and an amino acid sequence according to SEQ ID NO: 155, o. 006-H08-36-17-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 344, and an amino acid sequence according to SEQ ID NO: 366, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 178, and an amino acid sequence according to SEQ ID NO: 156, p. 006-H08-37-19-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 345, and an amino acid sequence according to SEQ ID NO: 367, and a light variable chain domain with a nucleic acid sequence according to SEQ ID NO: 179, and an amino acid sequence according to SEQ ID NO: 157, q. 006-H08-39-7 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 346, and an amino acid sequence according to SEQ ID NO: 368, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 180, and an amino acid sequence according to SEQ ID NO: 158, r. 006-H08-48-5 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 347, and an amino acid sequence according to SEQ ID NO: 369, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 181, and an amino acid sequence according to SEQ ID NO: 159, s. 006-H08-53-27-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 348, and an amino acid sequence according to SEQ ID NO: 370, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 182, and an amino acid sequence according to SEQ ID NO: 160, t. 006-H08-59-30-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 349, and an amino acid sequence according to SEQ ID NO: 371, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 183, and an amino acid sequence according to SEQ ID NO: 161, u. 006-H08-63-32-4 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 350, and an amino acid sequence according to SEQ ID NO: 372, and a light variable chain domain with a nucleic acid sequence according to SEQ ID NO: 184, and an amino acid sequence according to SEQ ID NO: 162, v. 006-H08-65-33-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 351, and an amino acid sequence according to SEQ ID NO: 373, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 185, and an amino acid sequence according to SEQ ID NO: 163, w. 006-H08-68-35-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 352, and an amino acid sequence according to SEQ ID NO: 374, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 186, and an amino acid sequence according to SEQ ID NO: 164.
[0023] In yet another embodiment, the antibody or antigen binding fragment of the aforementioned antibodies is disclosed by which to. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 29, or b. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 78, 24, 90, or c. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 75, 13, 82, 24, 91, or d. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 82, 24, 29, or e. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 86, 24, 29, or f. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 87, 24, 100, or g. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 87, 24, 92 or h. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 89, 24, 93 or i. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 79, 24, 101 or j. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 76, 13, 89, 24, 90 or k. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 100 or 1. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 97 or m. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 98 or n. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 83, 24, 99 or o. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 96 or p. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 18, 24, 94 or q. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 88, 24, 90 or r. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 74, 13, 81, 24, 95 or s. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 75, 13, 18, 24, 29 or t. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 77, 13, 18, 24, 29 or u. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 80, 24, 29 or v. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 85, 24, 29 or w. the antibody contains one, two, three, four, five or six of the CDRs that correspond to SEQ ID NO: 1, 7, 13, 84, 24, 29.
[0024] In another embodiment of the present invention, the 006-H08 antibody consists of an antigen binding region that specifically binds or has a high affinity for one or more PRLR regions, the amino acid sequence of which is described by SEQ ID NO: 70, amino acid position 1 to 210, whereby the affinity is at least 100 nM, preferably less than about 100 nM, more preferably less than about 30 nM, even more preferred with an affinity of less than about 10 nM or even more preferred with an affinity of less than 1 nM, or even more preferred with an affinity of less than 30 pM.
[0025] Also object of the present invention is the aforementioned antibody 006-H08, in which the heavy constant is a modified or unmodified IgG1, IgG2, IgG3 or IgG4.
[0026] Table 1 provides a summary of the dissociation constants and dissociation rates of the representative antibodies of the invention, as determined by surface plasmon resonance (Biacore) with monomeric PRLR extracellular domains (SEQ ID NO: 70) in directly immobilized antibodies . TABLE 1: MONOVALENT DISSOCIATION CONSTANTS AND EXTRACELLULAR DOMAIN DISSOCIATION FEES OF HUMAN PRLR EXPRESSED IN HEK293 CELLS DETERMINED FOR HUMAN ANTI-PRLR IgG1 MOLECULES THROUGH RESULT OF RESONANCE SURGERIES

[0027] The IgG1 format was used for the determination of cell-based affinity, determined by fluorescence-activated cell classification (FACS) combined with Scatchard analysis.
[0028] Table 2 denotes the binding resistance of the representative IgG antibodies in the human breast cancer cell line T47D and Nb2 mouse lymphoma cell line. TABLE 2: CELL-BASED BINDING POWER OF ANTI-PRLR ANTIBODIES AS DETERMINED BY FACS ON THE T47D HUMAN BREAST CANCER CELL LINE AND Nb2 RAT LYMPHOMA CELL LINE.
ANTIBODY GENERATION
[0029] To isolate a panel of antibodies capable of functionally blocking human and murine PRLR, two formats from the synthetic human antibody phage display library called Bioinvent n-CoDeR® (Soderlind et al. 2000, Nature Bio Technology. 18 , 852-856.), Expressing scFv and Fab fragments, respectively, were investigated in parallel. The targets used for scFv or Fab selection were the soluble ECD of human PRLR (amino acid positions 1 to 210 of SEQ ID NO. 70) and mouse PRLR (amino acid positions 1 to 210 of SEQ ID NO: 72), applied as a biotinylated variant (NHS-LC biotin, Pierce) and non-biotinylated as well as the human breast cancer cell line T47D expressing PRLR.
[0030] A combination of several approaches in phage display technology (PDT) has been used to isolate human, high-affinity, PRLR-specific monoclonal antibodies by a combination of protein and solid surface cell adherence (panning) techniques. entire cell and through the development of specific tools. Panning tools and screening methods include human and mouse PRLR ECD recombinantly expressed in fusion with an Fc domain (R&D Systems, catalog No. 1167-PR and 1309-PR, respectively; pos. 1-216 of SEQ ID NO: 70 and 72, respectively, each fused to the human IgG1 Fc domain, pos. 100 to 330 of human IgG1), the extracellular domain of human PRLR recombinantly expressed in fusion with a six histidine marker (SEQ ID NO: 70), HEK293 and the murine Ba / F lymphoma cell line each stably transfected with human and murine PRLR, respectively, and the T47D breast cancer cell line and the Nb2 mouse lymphoma cell each naturally expressing PRLR as well as the development of panning procedures and screening assays capable of identifying neutralizing antibodies that preferentially bind the PRLR displayed on the cell surface and that are cross-reactive with mouse and rat PRLR (see examples 6 and 10).
[0031] Screening was performed first by identifying the binders for human PRLR and eventually mouse PRLR in ELISA tests using recombinantly expressed antigens. Then, the cell binding of Fab and scFv fragments in T47D cells was examined by FACS analyzes followed by testing the neutralizing activity of these agents in intracellular signaling. For this purpose, inhibition of phosphorylation of PRLR, STAT5 and ERK1 / 2 in T47D cells was determined (see example 14). The best function that blocks scFvs and Fabs has been converted to the total IgG1 molecules and tested for monovalent affinities to the PRLR ECD and for inhibitory activity in luciferase reporter gene assays as well as in proliferation assays with cells that grow on prolactin dependence. The combination of these specific methods allowed the isolation of the new antibody "006-H08", object of the present invention, as well as the antibodies "002-H06", "002-H08", "006- H07", "001-E06", "005-C04", objects of the corresponding patent applications. PEPTIDE VARIANTS
[0032] The antibodies of the invention are not limited to the specific peptide sequences provided here. Preferably, the invention also incorporates variants of these polypeptides. With reference to immediate disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and use functional variants of the antibodies disclosed here, while appreciating that variants having the ability to functionally bind and block PRLR fall within the scope of the present invention.
[0033] A variant may include, for example, an antibody that has at least one altered complementarity determining region (CDR) (hyper-variable) and / or structure domain (FR) (variable), vis-à-vis -vis a peptide sequence revealed here. To better illustrate this concept, a brief description of the antibody structure follows.
[0034] An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the last of which is in each case composed of four regions of FR (VH: HFR1, HFR2, HFR3, HFR4; VL: LFR1, LFR2, LFR3, LFR4) and three interspersed CDRs (VL: LCDR1, LCDR2, LCDR3; VH: HCDR1, HCDR2, HCDR3). The antigen binding site is formed by one or more CDRs, yet the FR regions provide the structural structure for the CDRs and, consequently, play an important role in antigen binding. By altering one or more amino acid residues in a CDR or FR region, the skilled worker can usually generate mutated or diversified antibody sequences that can be screened against the antigen for new or improved properties, for example.
[0035] Figure 12 provides the schemes for numbering each amino acid position in the variable domains VL and VH. Tables 3 (VH) and 4 (VL) outline the CDR regions for certain antibodies of the invention and compare the amino acids in a given position with each other and with a corresponding consensus or "master gene" sequence, where the regions CDR numbers are marked with "X". Tables 5 and 6 help to assign SEQ ID Numbers to the antibodies, antibody fragments and PRLR variants provided in this invention. TABLE 3: VH SEQUENCES
TABLE 4: VL SEQUENCES
TABLE 5: ANTIBODY SEQUENCES

TABLE 6: SEQUENCES OF PRLR VARIANTS

[0036] The skilled worker can use the data in Tables 3, 4 and 5 to design the peptide variants that are within the scope of the present invention. It is preferred that the variants are constructed by changing the amino acids within one or more regions of CDR; a variant can also have one or more structure regions (FR) changed. For example, a peptide FR domain could be altered where there is a deviation in a residue compared to a germline sequence.
[0037] With reference to a comparison of new antibodies with the corresponding consensus or "master gene" sequence, which are listed in Fig. 12, candidate residues that can be altered include, for example, the following: - lysine residue (K) at position 75 for glutamine (Q) in VH 006-H08 (SEQ ID 34) - leucine residue (L) at position 108 for methionine (M) in VH 006-H08 (SEQ ID 34) - threonine residue (T ) at position 110 for isoleucine (I) in VH 006-H08 (SEQ ID 34) - phenylalanine residue (F) at position 67 for leucine (L) in VH 002-H08 (SEQ ID 36).
[0038] Furthermore, variants can be obtained by maturation, that is, using an antibody as a starting point for optimization by diversifying one or more amino acid residues in the antibody, preferably amino acid residues in one or more CDRs, and sorting the resulting collection from antibody variants to variants with improved properties. Particularly preferred is diversification of one or more amino acid residues in VL LCDR3, VH HCDR3, VL LCDR1 and / or VH HCDR2. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology [Virnekas, B., Ge, L., Pluckthun, A., Schneider, KC, Wellnhofer, G., and Moroney SE (1994 ) Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucletoides for random mutagenesis. Nucl. Acids Res. 22, 5600]. CONSERVATIVE AMINO ACID VARIANTS
[0039] Polypeptide variants can be made that retain the general molecular structure of an antibody peptide sequence described here. Given the properties of individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, i.e., "conservative substitutions", can be made, for example, based on similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of the residues involved.
[0040] For example, (a) non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions can typically be made within groups (a) - (d). In addition, glycine and proline can be substituted for each other based on their ability to break a-propellers. Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine, are more commonly found in α-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are found more commonly in β-pleated leaves. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in the loops. Some preferred substitutions can be made between the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the knowledgeable scientist can easily construct DNAs that encode conservative amino acid variants.
[0041] As used herein, "sequence identity" between two polypeptide sequences, indicates the percentage of amino acids that are identical between the sequences. "Sequence homology" indicates the percentage of amino acids that are identical or that represent conservative amino acid substitutions. Preferred polypeptide sequences of the invention have a sequence identity in the CDR regions of at least 60%, more preferably, at least 70% or 80%, even more preferably at least 90% and most preferably at least 95%. Preferred antibodies also have sequence homology in the CDR regions of at least 80%, more preferably 90% and most preferably 95%. However, all of these revealed molecules block prolactin receptor-mediated signaling. DNA MOLECULES OF THE INVENTION
[0042] The present invention also relates to DNA molecules that encode an antibody of the invention. These sequences include, but are not limited to, those DNA molecules exposed in SEQ ID NOs 46 and 52, and 331 to 374.
[0043] The DNA molecules of the invention are not limited to the sequences disclosed here, but also include their variants. DNA variants can be described within the invention with reference to their physical properties under hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is bifilament, its equivalent or homologous, using nucleic acid hybridization techniques. It will also be recognized that hybridization can occur with less than 100% complementarity. However, given the appropriate choice of conditions, hybridization techniques can be used to differentiate between DNA sequences based on their structural relationship to a particular probe. For guidance regarding these conditions, see, Sambrook et al., 1989 [Sambrook, J. Fritsch, EF and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA] and Ausubel et al., 1995 [Ausubel, FM Brent, R. Kingston, RE Moore, DD Sedman, JG Smith, JA & Struhl, K., eds. (1995). Current Protocols in Molecular Biology. New York: John Wiley and Sons].
[0044] Structural similarity between two polynucleotide sequences can be expressed as a function of "severity" of the conditions under which the two sequences will hybridize to each other. As used herein, the term "severity" refers to the extent that conditions disadvantage hybridization. Strict conditions strongly disadvantage hybridization, and only the most structurally related molecules will hybridize to each other under such conditions. Conversely, non-stringent conditions favor hybridization of the molecules exhibiting a lower degree of structural relationship. Therefore, the severity of hybridization correlates directly with the structural relationships of two nucleic acid sequences. The following relationships are useful in correlating hybridization and relationship (where Tm is the melting temperature of a nucleic acid doublet): a. Tm = 69.3 + 0.41 (G + C)% b. The Tm of a DNA doublet decreases by 1 ° C with each 1% increase in the number of unpaired base pairs. ç. (Tm) μ2 - (Tm) μ1 = 18.5 log10μ2 / μ1
[0045] where μ1 and μ2 are the ionic resistances of the two solutions.
[0046] Severity of hybridization is a function of many factors, including general DNA concentration, ionic resistance, temperature, probe size and the presence of agents that break the hydrogen bond. Factors that promote hybridization include high DNA concentrations, high ionic resistance, low temperatures, longer probe size and the absence of agents that break the hydrogen bond. Hybridization is typically performed in two phases: the "binding" phase and the "washing" phase.
[0047] First, in the ligation phase, the probe is attached to the target under conditions that favor hybridization. Severity is usually controlled at this stage by changing the temperature. For high severity, the temperature is usually between 65 ° C and 70 ° C, unless short (<20 nt) oligonucleotide probes are used. A representative hybridization solution comprises 6x SSC, 0.5% SDS, 5x Denhardt solution and 100 μg of non-specific vehicle DNA [see Ausubel et al., Section 2.9, supplement 27 (1994)]. Of course, many different buffer conditions, although functionally equivalent, are known. Where the degree of relationship is lower, a lower temperature can be selected. Low severity bonding temperatures are between about 25 ° C and 40 ° C. Average severity is between at least about 40 ° C unless about 65 ° C. High severity is at least about 65 ° C.
[0048] Second, the excess probe is removed by washing. It is at this stage that the most stringent conditions are usually applied. Consequently, it is this stage of "washing" that is very important in determining the relationship through hybridization. Washing solutions typically contain lower salt concentrations. An exemplary medium severity solution contains 2X SSC and 0.1% SDS. A high severity wash solution contains the equivalent (in ionic strength) of less than about 0.2X SSC, with a preferred stringent solution containing about 0.1X SSC. The temperatures associated with the various severities are the same as discussed above for "binding". The wash solution is also typically replaced several times during the wash. For example, typical washing conditions of high severity include washing twice for 30 minutes at 55 ° C and three times for 15 minutes at 60 ° C.
Accordingly, the object of the present invention is an isolated nucleic acid sequence encoding the antibody and antigen binding fragments of the present invention.
[0050] Another embodiment of the present invention is the aforementioned isolated nucleic acid sequence that encodes the antibodies of the present invention by means of which the nucleic acid sequences are as given in table 5.
Accordingly, the present invention includes nucleic acid molecules that hybridize to the molecules as set out in Table 5 under conditions of high stringency and washing where such nucleic molecules encode an antibody or functional fragment thereof having properties as described herein.
Preferred molecules (from an mRNA perspective) are those that have at least 75% or 80% (preferably at least 85%, more preferably at least 90% and most preferably at least 95%) of sequence identity with one of the DNA molecules described here. The molecules block prolactin receptor-mediated signaling. FUNCTIONALLY EQUIVALENT VARIABLES
[0053] Yet another class of DNA variants within the scope of the invention can be described with reference to the product they encode. These functionally equivalent genes are characterized by the fact that they encode the same peptide sequences found in SEQ ID NO: 34-45 due to the degeneration of the genetic code.
[0054] It is recognized that the DNA molecule variants provided here can be constructed in several different ways. For example, they can be constructed as completely synthetic DNA. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel et al., Section 2.11, Supplement 21 (1993). Overlapping oligonucleotides can be synthesized and assembled in a manner first reported by Khorana et al., J. Mol. Biol. 72: 209-21 (1971); see also Ausubel et al., supra, Section 8.2. Synthetic DNAs are preferably designed with convenient restriction sites engineered at the 5 'and 3' ends of the gene to facilitate cloning into an appropriate vector.
[0055] As indicated, one method of generating variants is to start with one of the DNAs revealed here and then conduct targeted mutagenesis. See Ausubel et al., Supra, chapter 8, Supplement 37 (1997). In a typical method, target DNA is cloned into a single-stranded bacteriophage vehicle. The single-stranded DNA is isolated and hybridizes to an oligonucleotide containing the desired nucleotide change (s). The complementary filament is synthesized and the bifilament phage is introduced into a host. Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing. In addition, several methods are available that increase the likelihood that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available to generate such mutants. RECOMBINANT DNA CONSTRUCTIONS AND EXPRESSION
[0056] The present invention further provides recombinant DNA constructs that comprise one or more of the nucleotide sequences of the present invention. The recombinant constructs of the present invention are used with respect to a vector, such as a plasmid, phagemid, phage or viral vector to which a DNA molecule encoding an antibody of the invention is inserted.
[0057] The encoded gene can be produced by techniques described in Sambrook et al., 1989, and Ausubel et al., 1989. Alternatively, DNA sequences can be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in Oligonucleotide Synthesis (1984, Gait, ed., IRL Press, Oxford), which is incorporated herein by reference in its entirety. The person skilled in the field is able to fuse the DNA encoding the variable domains with gene fragments which encode the regions contained in various isotypes of human IgG or derived from them, mutated or non-mutated. It is capable of applying recombinant DNA technology to fuse both variable domains into a single-stranded format using linkers such as a fifteen-amino acid extension containing three times glycine-glycine-glycine-glycine-serine. The recombinant constructs of the invention are comprised of expression vectors that are capable of expressing the RNA and / or protein products of the encoded DNA (s). The vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF). The vector may further comprise a selectable marker sequence. Specific initiation and bacterial secretory signals may also be required for efficient translation of the inserted target gene coding sequences.
[0058] The present invention further provides host cells containing at least one of the DNAs of the present invention. The host cell can be virtually any cell for which expression vectors are available. It may, for example, be an upper eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, and it may be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct in the host cell can be performed by calcium phosphate transfection, DEAE, dextran-mediated transfection, electroporation or phage infection. BACTERIAL EXPRESSION
[0059] Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence that encodes a desired protein together with appropriate translation initiation and termination signals and in readable phase operable with a functional promoter. The vector will comprise one or more selectable phenotypic markers and an origin of replication to ensure maintenance of the vector and, if desired, provide amplification within the host. Prokaryotic hosts suitable for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and several species within the genera Pseudomonas, Streptomyces, and Staphylococcus.
[0060] Bacterial vectors can be, for example, based on bacteriophage, plasmid or phagemid. These vectors can contain a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing well-known cloning vector elements pBR322 (ATCC 37017). Following the transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is decompressed / induced by appropriate means (for example, temperature shift or chemical induction) and the cells are grown for a period additional. The cells are typically harvested by centrifugation, broken by physical or chemical means, and the resulting crude extract retained for further purification.
[0061] In bacterial systems, several expression vectors can be advantageously selected depending on the intended use for the protein being expressed. For example, when a large amount of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors that direct the expression of high levels of fusion protein products that are easily purified can be desirable.
[0062] Therefore, an object of the present invention is an expression vector comprising a nucleic acid sequence that codes for new antibodies of the present invention. MAMMALIAN EXPRESSION & PURIFICATION
Preferred regulatory sequences for mammalian host cell expression include viral elements that target high levels of protein expression in mammalian cells, such as promoters and / or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter / enhancer ), Simian Virus 40 (SV40) (such as the SV40 promoter / enhancer), adenovirus, (e.g., the major adenovirus late promoter (AdMLP)) and polyoma. For further description of viral regulatory elements, and their sequences, see, for example, U. S. 5,168,062 by Stinski, U. S. 4,510,245 by Bell et al. and U. S. 4,968,615 by Schaffner et al. Recombinant expression vectors can also include origins of replication and selectable markers (see for example, U. S. 4,399,216, 4,634,665 and U. S. 5,179,017, by Axel et al.). Suitable selectable markers include genes that confer resistance to drugs such as G418, hygromycin or methotrexate, in a host cell to which the vector has been introduced. For example, the dihydrofolate reductase (DHFR) gene confers resistance to methotrexate and the gene does not confer resistance to G418.
[0064] Transfection of the expression vector in a host cell can be performed using standard techniques such as electroporation, calcium-phosphate precipitation, and DEAE-dextran transfection.
[0065] Mammalian host cells suitable for expressing the antibodies, antigen binding portions, or derivatives thereof provided herein include Chinese Hamster Ovaries (CHO cells) [including CHO-dhfr cells, described in Urlaub and Chasin, (1980) Proc . Natl. Acad. Sci. USA 77: 4216-4220, used with a selectable DHFR marker, for example, as described in R. J. Kaufman and P. A. Sharp (1982) Mol. Biol. 159: 601-621]], NSO myeloma cells, COS cells and SP2 cells. In some embodiments, the expression vector is designed so that the expressed protein is secreted into the culture medium in which the host cells are grown. Antibodies, antigen binding moieties, or derivatives thereof can be recovered from the culture medium using standard protein purification methods.
[0066] Antibodies of the invention or an antigen binding fragment thereof can be recovered and purified from recombinant cell cultures by well-known methods including, but not limited to, ammonium sulfate or ethanol precipitation, acid extraction, chromatography Protein A, Protein G chromatography, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography ("HPLC") can also be used for purification. See, for example, Colligan, Current Protocols in Immunology, or Current Protocols in Protein Science, John Wiley & Sons, NY, NY, (1997-2001), for example, Chapters 1, 4, 6, 8, 9, 10, each completely incorporated here by reference.
[0067] Antibodies of the present invention or antigen binding fragment thereof include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a eukaryotic host, including, for example, yeast, taller plant, insect and mammalian cells. Depending on the host employed in a recombinant production procedure, the antibody of the present invention can be glycosylated or non-glycosylated. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Sections 17.37-17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18 and 20.
Therefore, an object of the present invention is also host cells comprising the vector or a nucleic acid molecule, whereby the host cell can be a superior eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell. , such as a yeast cell, and can be a prokaryotic cell, such as a bacterial cell.
[0069] Another object of the present invention is a method of using the host cell to produce an antibody and antigen binding fragments, comprising culturing the host cell under suitable conditions and recovering said antibody.
Therefore, another object of the present invention is the antibody as described in the present invention produced with the host cells of the present invention and purified to at least 95% homogeneity by weight. ENDOMETRIOSIS AND ADENOMIOSIS (INTERNAL ENDOMETRIOSIS)
[0071] Endometriosis is a benign, estrogen-dependent, gynecological disorder that is characterized by the presence of endometrial tissue (glands and stroma) outside the uterine cavity. Endometriotic lesions are mainly found in the pelvic peritoneum, in the ovaries and in the rectovaginal septum (Obstet. Gynecol. Clin. North. Am. 24: 235-238, 1997). Endometriosis is often associated with infertility and pain symptoms such as dysmenorrhea. In addition, many patients suffer from autoimmune diseases (Hum. Reprod. 17 (19): 2715-2724, 2002). Adenomyosis uteri also known as internal endometriosis describes a subform of endometriosis that is restricted to the uterus. In the case of adenomyosis uteri, the endometrial glands invade the myometrium and the uterine wall.
[0072] According to transplantation theory, endometrial fragments are flowed through retrograde menstruation in the peritoneal cavity in both healthy patients and women (Obstet. Gynecol. 64: 151-154, 1984). Four main factors appear to be critically involved in the successful establishment of endometriotic lesions in the pelvic cavity of patients: (a) In the late secretory phase of the menstrual cycle, endometrial cells in healthy women become apoptotic. In patients, the extent of apoptosis in endometrial cells is clearly reduced (Fertil. Steril. 69: 1042-1047,1998). Therefore, in patients there is a higher probability than in healthy women, those endometrial fragments that have been flowed into the peritoneal cavity through retrograde menstruation do not die and implant themselves successfully. (b) For successful implantation in the peritoneum and long-term survival of ectopic endometrial fragments, new blood vessels must be formed (British Journal of Pharmacology, 149: 133-135, 2006). (c) Many patients suffer from autoimmune disease and thus have an impaired immune system (Hum. Reprod. 17 (19): 2002, 2715-2724, 2002). This may lead to the conclusion that an intact immune response - as it is present in healthy women - can play a role in preventing the establishment of endometriotic lesions. (d) The lesions have to grow and thus depend on the presence of mitogenic stimuli and growth factors.
[0073] For the treatment of endometriosis, the following approaches currently exist: (a) Gonadotropin releasing hormone analogs (GnRH): lead to suppression of ovarian estradiol synthesis and induce atrophy of ectopic endometriotic implants that critically depend on the presence of estradiol for growth. (b) Aromatase inhibitors: inhibit the local production of estradiol by means of endometriotic implants, induce apoptosis and inhibit the proliferation of ectopic endometriotic fragments. (c) Selective estrogen receptor modulators: have estrogen receptor antagonistic activity in normal and ectopic endometrial implants and thus lead to atrophy of the implanted ectopic endometriotic tissue. (d) Progesterone receptor agonists: inhibit the proliferation of normal and ectopic endometrial cells, induce differentiation and apoptosis. (e) Combined oral condoms: maintain the status quo, prevent disease progression, and induce ectopic and eutopic endometrial atrophy. (f) Surgical excision of the lesions.
[0074] GnRH analogs, SERMs, and aromatase inhibitors have severe side effects and lead to hot flushes and bone loss in young women who suffer from endometriosis. Treatment with progesterone receptor agonists leads to inhibition of ovulation, irregular menstrual bleeding followed by amenorrhea, body weight gain and depression. Due to the increased risk for venous thromboembolism, combined oral condoms are not indicated for women over the age of 35, smokers and individuals who are overweight. Surgical excision of the lesions is prone to high recurrence rates.
[0075] The antibodies of the present invention interfere with PRLR-mediated signaling stimulated by pituitary and locally produced prolactin or due to activation of PRLR mutations and are therefore more effective than dopamine-2 receptor agonists that interfere only with secretion of pituitary prolactin.
[0076] Therefore, an object of the present invention is the 006-H08 antibody or antigen binding fragments as a drug.
[0077] PRL and PRLR are expressed in the uterus and play a role in normal uterine physiology; PRL can act as a potent mitogen and can play an immunomodulatory role. In the present invention it is shown that changes in the PRL / PRLR system play a role in human endometriosis. An analysis of PRL and PRLR expression in healthy women's endometrium and in patient's endometrium and lesions (see Example 2) by Taqman's quantitative PCR is shown in Figures 1 and 2.
[0078] As shown in Figure 1 (PRL expression) and Figure 2 (PRLR expression), both PRL and its receptor are strongly overloaded in endometriotic lesions. This finding generates experimental evidence for the first time that autocrine PRL signaling may play a fundamental role in the establishment, growth, and maintenance of endometriotic lesions.
[0079] PRLR antibodies have been successfully tested in an animal model for internal endometriosis, that is, adenomyosis uteri in mice (see Example 20). Adenomyosis is characterized by infiltrative growth of the endometrial glands in the myometrial layer of the endometrium. It resembles a form of endometriosis restricted to the uterus - the only form of endometriosis that species that do not menstruate can develop. Danazol, which is effective in the clinical treatment of patients suffering from endometriosis, is also effective in the treatment of adenomyosis uteri (Life Science 51: 1119-1125, 1992). However danazol is an androgenic progestin and leads to severe androgenic side effects in young women, which limits its use.
[0080] The antibodies of the present invention solve the problem by providing new treatments or prevention for endometriosis and have fewer side effects than current standard therapies.
Therefore, another aspect of the present invention is to employ neutralizing antibodies to PRLR and antigen binding fragments for the treatment or prevention of endometriosis and adenomyosis (internal endometriosis).
[0082] Another aspect of the present invention is the use of the antibody and antigen binding fragments as described in the present invention for the treatment or prevention of endometriosis and adenomyosis (internal endometriosis). NON-HORMONAL FEMALE CONTRACEPTION
[0083] Current approaches to female contraception are as follows: (a) Combined oral condoms containing estrogens and progestins. The progestogenic component mediates the contraceptive effect through negative feedback on the hypothalamic-pituitary-gonadic axis. The estrogenic component ensures good control of hemorrhage and enhances gestagenic action by inducing the progesterone receptor in target cells. (b) Intrauterine devices containing progestins only. Locally released progestin gives the endometrium an implant-resistant state. In addition, cervical mucus is almost impermeable to sperm cells. (c) Progestin only pills and implants. Progestin inhibits ovulation through negative feedback on the hypothalamic-pituitary-gonadic axis. In addition, the permeability of cervical mucus to sperm cells is reduced. (d) Vaginal rings containing ethinyl estradiol plus progestins.
[0084] The main side effect of combined oral condoms is the high risk for venous thromboembolism (VTE). In addition, overweight women or smokers, as well as women suffering from autoimmune diseases such as lupus and women over the age of 35, cannot use combined oral condoms.
[0085] Intrauterine devices and implants containing progestins can only lead to dysfunctional uterine bleeding.
[0086] Progestin-only pills can cause irregular bleeding patterns, spotting, amenorrhea. The risk for ectopic pregnancies increases. Weight gain and reductions in bone mass density are other side effects.
[0087] Vaginal rings can lead to vaginitis, leukorrhea or expulsion.
[0088] PRLR-deficient mice were spawned a few years ago (Genes Dev 11: 167-178, 1997). Interestingly, PRLR-deficient females, but not male mice, are completely sterile. PRLR - / - females showed an apprehension of egg development immediately after fertilization, that is, they showed an apprehension of pre-implantation development. Only very few oocytes reached the blastocyst stage and were unable to implant in mutant females but developed into normal embryos in wild-type mothers after transplantation. The infertility phenotype of PRLR-deficient mice could be saved up to mid-pregnancy through progesterone supplementation. Obviously, PRLR-mediated signaling plays an important role in the maintenance and function of the corpus luteum by producing progesterone that is necessary to allow and maintain pregnancy. In addition, PRLR-deficient females, but not males, showed a reduction in body weight associated with a reduction in abdominal fat mass and leptin levels.
[0089] Until now, no inactivating human PRLR mutation is known, so the precise role of PRLR-mediated signaling in human fertility is still unknown. However, there is growing evidence that also in humans, a minimum level of prolactin is required to allow successful pregnancy. Patients suffering from primary infertility due to insufficient hyperprolactinemic corpus luteum were treated with bromocriptine. In some cases, prolactin levels have been suppressed and the shortened luteal phases reappeared again (Bohnet HG et al. In Lisuride and the other dopamine agonists edited by D. B. Calne et al, Raven Press, New York, 1983). From these data, it was concluded that hyper and hypoprolactinemic states interfere negatively with female fertility. This can be explained by the interaction of PRL with its receiver. In the case of low prolactin levels, there is no sufficient receptor activation, whereas in the case of hyperprolactinemia, there is also no sufficient receptor activation, since all receptors are blocked by a prolactin molecule and cannot dimerize more. In other words, the dose response to prolactin is bell-shaped and optimal receptor activation is achieved only within a certain concentration range. There is evidence from a second study that lack of endometrial prolactin expression in patients leads to premature implantation failure (Human Reprod. 19: 1911-1916, 2004). In addition, it has been shown that ex vivo, prolactin can prevent apoptosis of cultured human granulosa cells and thereby maintain premature corpus luteum function as demonstrated in PRLR-deficient mice (Human Reprod. 18: 2672-2677,2003).
[0090] To test the contraceptive efficacy of PRLR neutralizing antibodies, the mice were injected with specific and non-specific PRLR antibodies and mated with males as described in example 11. Readings were the litter number per treatment group and litter size per animal. The experiment shown in figure 11 demonstrates that treatment with the neutralizing antibody of the present invention completely prevented pregnancy in mice when tested at 30 mg / kg of body weight.
[0091] Compared to the standard approaches mentioned above, female contraception with neutralizing PRLR antibodies has several advantages: ■ the antibodies can be used in smoking, overweight, and older women as well as in women suffering from lupus erythematosus (PRLR antibodies they could even be beneficial for the treatment of lupus and the reduction of abdominal fat, that is, PRLR-deficient mice had less abdominal fat). ■ PRLR antibodies do not increase the risk of VTE (venous thromboembolic). ■ in contrast to the estrogens and progestins used in combined oral contraception, neutralization of PRLR-mediated signaling leads to inhibition of epithelial proliferation of the breast and in contrast to hormonal approaches to fertility control could even protect users from breast cancer. mama.
[0092] Another objective of the present invention is the use of PRLR neutralizing PRLR antibodies and antigen binding fragments for female contraception with reduced side effects compared to standard treatments.
[0093] Another aspect of the present invention is the use of the antibody and antigen binding fragments as described in the present invention for female contraception with reduced side effects compared to standard treatments. BENIGNA BREAST DISEASE AND MASTALGIA
[0094] Benign breast disease covers a variety of symptoms, such as fibrocystic breast disease, fibroadenoma, mastalgia, and macrocysts. 30 - 50% of pre-menopausal women suffer from fibrocystic breast disease (Epidemiol Rev 19: 310-327, 1997). Depending on the age of women, benign breast disease may present with different phenotypes (J Mammary Gland Biol Neoplasia 10: 325-335, 2005): during premature reproductive phases (15 - 25 years) when lobular development in the normal breast occurs , benign breast disease results in fibroadenomas. Single giant fibroadenomas as well as multiple adenomas are observed. These fibroadenomas are composed of stromal as well as epithelial cells and arise from the lobules. In the mature reproductive phase (25 - 40 years), the breast is subject to cyclical changes during each menstrual cycle. Sick women have cyclic mastalgia and several lumps in their breast. Afterwards (35-55 years of age), the normal breast is involute while in the sick breast macrocysts and epithelial hyperplasia with and without atypia can be observed. Those forms of benign breast disease that are accompanied by increased proliferation of epithelial cells are at a higher risk for developing breast carcinomas. This risk can be up to 11% if cell atypias are present in the proliferative cell fraction (Zentralbl Gynakol 119: 54-58,1997). 25% of women aged 60 - 80 years also suffer from benign breast disease, often estrogen replacement therapy or adiposity are the reasons for persisting benign breast disease after menopause (Am J Obstet Gynecol 154: 161-179 , 1986).
[0095] The pathophysiology of fibrocystic breast disease is determined by predominance of estrogen and progesterone deficiency resulting in hyperproliferation of connective tissues (fibrosis) which is followed by proliferation of facultative epithelial cell. As already mentioned, the risk of breast cancer is high in patients who exhibit increased proliferation of epithelial cells within the fibrocystic foci. Clinically, fibrocystic breast disease presents with pain in the breast and tenderness in the breast. 70% of patients with fibrocystic breast disease suffer from any insufficiency of the corpus luteum or anovulation (Am J Obstet 154: 161- 179,1986). Deficiency of the corpus luteum results in reduced progesterone levels and a predominance of estrogen.
[0096] Mastalgia (pain in the breast) affects about 70% of women at some point in their reproductive life period. Breast pain may or may not be associated with other premenstrual syndrome criteria. It has been shown that women suffering from mastalgia respond with an excess prolactin release after stimulation of the hypothalamic-pituitary axis (Clin Endocrinol 23: 699-704.1985).
[0097] Standard therapies for benign breast disease and mastalgia are: 1) Bromocriptine
[0098] Bromocriptine as a dopamine agonist blocks only the synthesis of pituitary prolactin, but not the local synthesis of prolactin in mammary epithelial cells. It is, therefore, only effective in those forms of mastalgia and benign breast disease that have high levels of systemic prolactin. Main side effects of bromocriptine are:
[0099] Nausea, vomiting, edema, hypotension, dizziness, hair loss, headache, and hallucinations. 2) Danazol
[00100] Danazol is an androgenic progestin that, through its antigonadotrophic activity //, combats the predominance of estrogen observed in benign breast disease. Main side effects are:
[00101] Menstrual irregularities, depression, acne, hirsutism, deep voice, and hot flushes as well as weight gain. 3) Tamoxifen
[00102] Tamoxifen is a selective estrogen receptor modulator with antiestrogenic activity in the breast and estrogenic activity in the uterus. Main side effects are:
[00103] postmenopausal symptoms such as bone loss and hot flushes, ovarian cysts, and endometrial carcinoma. 4) Progestins
[00104] Progestins inhibit benign breast disease through suppression of the gonadic-pituitary axis, inhibition of ovulation and estrogen depletion. Estrogen depletion leads to symptoms of menopause such as bone loss and hot flushes. 5) Low-dose combined oral condoms
[00105] This treatment is not indicated for women over 35 years of age, smoking patients as well as diabetics and overweight.
[00106] In general, prolactin levels have been found to be increased by one third of women with benign breast disease. Considering that estrogens intensify the secretion of pituitary prolactin, it is believed that the increase in serum prolactin levels is a consequence of the predominance of estrogens in this disease. An activating PRLR mutation has been reported to be frequently present in women suffering from multiple breast adenomas - resembling a subtype of fibrocystic breast disease (Paul Kelly, Breast Congress Turin, 2007 and Proc Natl Acad Sci 105: 14533- 14538; 2008).
[00107] Benign breast disease, mastalgia and premenstrual breast tension have a common pathophysiological mechanism: enhanced prolactin signaling. Elevated prolactin signaling may be the consequence of: ■ systemic hyperprolactinemia (due to pituitary adenoma) ■ local hyperprolactinemia (due to prolactin synthesis proliferating epithelial cells in the mammary gland). Local hyperprolactinemia does not translate into high blood prolactin levels. ■ constitutively activating PRLR signaling in the presence of normal prolactin levels (due to an activating PRLR mutation).
[00108] Given that certain forms of benign breast disease can give rise to breast cancer, there is a medical need for the treatment of this disease.
[00109] To demonstrate the effectiveness of neutralizing PRLR antibodies in a preclinical model of benign breast disease, a mouse model based on systemic hyperprolactinemia was used. Adult Balb / c mice were transplanted with pituitary isografts under the kidney capsule as described in Example 16 (In: Methods in Mammary gland Biology and Breast Cancer Research, 101-107,2000). Systemic hyperprolactinemia caused increased proliferation of epithelial cells in the mammary gland, and stimulated bifurcation and lobuloalveolar development compared to untreated, untreated control mice. The most severe forms of human fibrocystic breast diseases that carry an increased risk of cancerous development are characterized by increased proliferation of epithelial cells. As described in Example 16, neutralizing PRLR antibodies were tested in this Balb / c mouse model against non-specific antibodies with respect to their ability to: ■ block bifurcation and lobuloalveolar development ■ inhibit the proliferation of breast epithelial cells ■ inhibit phosphorylation of STAT5, a transcription factor that is normally activated and phosphorylated after activation of PRLR.
[00110] As shown in Figure 15A-C neutralizing PRLR antibodies block all of the aforementioned reading paradigms in a dose-dependent manner.
[00111] Another object of the present invention is the use of neutralizing antibodies to PRLR or antigen binding fragments for the treatment of benign breast disease and mastalgia in pre- or post-menopausal women.
[00112] Another aspect of the present invention is the use of antibodies or antigen binding fragments as described in the present invention for the treatment of benign breast disease and mastalgia in pre- or post-menopausal women. LACTATION INHIBITION
[00113] Prolactin is the main hormone involved in lactation after the birth of the child. This is confirmed by the phenotype of PRLR-deficient mice. Even heterozygous mice have severe lactation problems and cannot completely feed their offspring (Frontiers in Neuroendocrinology 22: 140-145, 2001).
[00114] For many reasons, women have to stop breastfeeding, that is, maternal delivery of drugs potentially dangerous to the infant, serious infections (mastitis, nephritis), profuse postpartum hemorrhage, and severe maternal diseases such as diabetes , carcinoma, and weakness or diseases of the newborn. Currently, dopamine receptor agonists such as bromocriptine and lisuride are used to inhibit lactation after the child's birth. However, these compounds can cause severe side effects such as nausea, vomiting, edema, hypotension, dizziness, hair loss, headache, and hallucinations. In addition, dopamine receptor agonists are not indicated in women suffering from cardiovascular disease and hypertension. Another disadvantage of bromocriptine is its short half-life, requiring daily drug delivery 4-6 times over a period of 14 days.
[00115] To test the effectiveness of prolactin receptor neutralizing antibodies in mice, NMRI mice were mated with males. After birth, litter size was determined in 8 animals, and the females were treated with specific and non-specific antibodies directed against the PRLR as described in example 15. As a measure for maternal lactation capacity, the weight of the offspring was monitored daily . Readings are described in detail in example 15 and the results are described in figure 14A-D. Neutralizing PRLR antibodies show dose-dependent inhibition of lactation and lead to involution of the mammary gland and reduced milk protein production.
[00116] Another objective of the present invention is the use of PRLR neutralizing antibodies for inhibition of lactation.
[00117] Another objective of the present invention is the use of the 006-H08 antibody and antigen binding fragments as described in the present invention for inhibition of lactation. BENIGNA PROSTATE HYPERPLASIA
[00118] Benign prostatic hyperplasia (BPH) is the fourth most prevalent medical care condition in older men. Prostate enlargement is a progressive age-dependent condition that affects more than 50% of men> 50 years of age. BPH is characterized by hyperplasia of the prostatic epithelial and stromal cells, resulting in the formation of distinct large nodules in the periurethral region of the prostate that compresses the urethral canal. Thus, impaired urine flow is a major consequence of BPH.
[00119] Standard BPH therapies include: (a) a1-adrenergic receptor antagonists (eg, tamsulosin, alfuzosin, terazosin, doxazosin) alleviate the symptoms of BPH in the lower urinary tract. They decrease bladder outlet obstruction by blocking alpha-receptor mediated stimulation of prostate smooth muscle. Major side effects are vasodilating adverse events, dizziness and ejaculation failure. (b) 5α-reductase inhibitors (for example finasteride)
[00120] 5α-reductase inhibitors prevent the formation of dihydrotestosterone, the active form of testosterone in the prostate that is responsible for prostate enlargement. Main side effects are sexual dysfunction, such as erectile disorders and decreased libido. (c) Transurethral resection of the prostate (TURP)
[00121] This surgical treatment is associated with high morbidity. Side effects are bleeding, incontinence, restriction formation, loss of ejaculation, and perforation of the bladder. (d) Prostate stent placement
[00122] A stent is inserted into the prostatic part of the urethra to ensure proper flow of urine. Main side effects are fouling, urinary tract infection, and stent migration. In addition, stents must be removed before any transurethral manipulation.
[00123] As described for the mammary gland, PRL and PRLR act in an autocrine / paracrine way (J. Clin. Invest. 99: 618 pages 1997) within the prostate.
[00124] Clinical studies indicate that hyperprolactinemia (and agromegaly) is associated with prostatic enlargement and stromal accumulation of inflammatory cells. Human growth hormone can bind to human PRLR in the presence of zinc which could explain why acromegaly can lead to benign prostatic hyperplasia. Serum PRL levels are often elevated in patients with BPH.
[00125] Transgenic animals that ubiquitously overexpress the PRL gene develop severe stromal prostate hyperplasia, indicating PRL as an important pathophysiological factor for the development of prostate hyperplasia (Endocrinology 138: 4410 pages, 1997). In addition, local PRL overexpression in transgenic mice under the prostate-specific probasin promoter results in stromal expansion, inflammatory cell accumulation and focal epithelial dysplasia, which are basic features of human BPH (Endocrinology 144: 2269 pages, 2003) .
[00126] PRLR is highly expressed in the prostate gland (Example 3, Figure 3). Variation of PRLR protein expression was observed in rat prostate tissue after hormone depletion and treatment (Example 4, Figure 4). In addition to PRLR, prostate cells also express prolactin.
[00127] As described in Example 17, male Balb / c mice received pituitary isografts under the renal capsule and benign prostatic hyperplasia developed. The effect of neutralizing antibodies on the prolactin receptor and non-specific antibodies on benign prostatic hyperplasia was tested in this model. The reading paradigms are described in Example 17. As described in Figure 16, neutralizing antibodies to PRLR inhibit benign prostate growth and are therefore suitable for the treatment of benign prostatic hyperplasia.
[00128] Another objective of the present invention is the use of neutralizing PRLR antibodies or antigen binding fragments for the treatment of benign prostatic hyperplasia.
[00129] Another aspect of the present invention is the use of the antibody or antigen binding fragments as described in the present invention for the treatment of benign prostatic hyperplasia. HYPERPROLACTINEMIC HAIR LOSS
[00130] Hair loss treatment is still an unmet need. Scalp hair growth in cycles: the anagen phase is characterized by active hair growth, the catagen phase shows involution and is followed by the telogen phase (fall). The exogenous phase (the release of dead hair) coincides with the end of the telogen phase. Hair loss can be the consequence of altered hair growth at any stage.
[00131] Telogen hair loss can have many triggers (physiological and emotional tension, medical conditions, iron and zinc deficiency), especially androgenic alopecia in its premature stages shows hair shortening of the telogen phase (Cleveland clinic journal of medicine 2009; 76 : 361-367). Anagen hair loss is often the result of radiation or chemotherapy.
[00132] Minoxidil and Finasteride are used to treat androgenetic hair loss, while glucocorticoids are used for alopecia areata. In general, all of these treatments have side effects (finasteride: loss of libido and impotence in men, glucocorticoids: diabetes, weight gain, osteoporosis), and the problem of treating hair loss has not been completely solved.
[00133] In rodents, shaving experiments on adult animals were used to analyze the effect of compounds on hair loss using hair regrowth on the shaved area as a reading paradigm (British Journal of Dermatology 2008; 159: 300-305). Scraping of adult animals (hair mainly in the telogen phase) induces the anagen phase that is characterized by hair growth.
[00134] In the experiments as described in Example 17 (benign prostatic hyperplasia), animals receiving pituitary isografts were scraped. In the course of these experiments, it was unexpectedly discovered that animals that received pituitary isografts showed severe hair regrowth damage in the shaved area. Treatment with neutralizing antibodies to PRLR, but not with non-specific antibodies, stimulated hair growth (Figure 17).
[00135] This observation demonstrates that elevated prolactin receptor-mediated signaling is involved in hair loss. To analyze this in more detail, other scraping experiments in close analogy to the previously described experiments were performed (British Journal of Dermatology 2008; 159: 300-305). These additional scraping experiments are described in Example 18. The experiments demonstrate that neutralizing PRLR antibodies stimulate hair growth in hyper and normoprolactinemic male and female mice.
[00136] The antibodies of the present invention solve the problem to provide new treatments for hyper and normoprolactinemic hair loss in women and men.
[00137] Therefore, another aspect of the present invention is to employ neutralizing antibodies to PRLR or antigen binding fragments for the treatment or prevention of hyper and normoprolactinemic hair loss.
[00138] Another aspect of the present invention is the use of the antibody or antigen binding fragments as described in the present invention for the treatment or prevention of hyperprolactinemic hair loss. COMBINED HORMONAL THERAPY
[00139] For the treatment of hot flushes in postmenopausal women who still have a uterus, combinations of estrogen (estradiol, or conjugated equine estrogens = EEC) and progestins (eg, medroxyprogesterone acetate (MPA), progesterone, drospirenone, levonorgestrel) were used. Progestins have to be added to inhibit estradiol-activated uterine epithelial cell proliferation. However, the addition of progestins increases the proliferation of breast epithelial cells. Since both normal and cancerous breast epithelial cells respond with proliferation to combined estrogen plus progestin treatment, the relative risk of breast cancer was observed to be increased after CEE plus MPA treatment (JAMA 233: 321-333; 2002) .
[00140] Neutralizing PRLR antibodies when administered every month or every second month to women on combined hormone therapy will inhibit enhanced proliferation of mammary epithelial cells.
[00141] As described in Example 19, a mouse model previously developed for the quantitative analysis of the effects of progestin on the uterus and breast was employed (Endocrinology 149: 3952-3959,2008). Mice were ovariectomized and were treated 14 days after ovariectomy for three weeks with vehicle or 100 ng estradiol plus 100 mg / kg progesterone to mimic hormone replacement therapy. The animals were treated once weekly with specific PRLR (10 mg / kg or 30 mg / kg) or non-specific antibodies (30 mg / kg). The effects of PRLR neutralizing antibodies on proliferative activity in the breast under combined hormone therapy were analyzed.
[00142] The antibodies of the present invention solve the problem to treat intensified proliferation of mammary epithelial cells observed under combined hormone therapy.
[00143] Another object of the present invention is the use of neutralizing PRLR antibodies or antigen-binding fragments in combined hormonal therapy (i.e., estrogen + progestin therapy) to inhibit proliferation of breast epithelial cells.
[00144] Another aspect of the present invention is the use of the antibody or antigen binding fragments as described in the present invention in combined hormonal therapy (i.e., estrogen + progestin therapy) to inhibit proliferation of breast epithelial cells. DEFINITIONS
The target antigen human "PRLR" as used herein refers to a human polypeptide having substantially the same amino acid sequence in its extracellular domain as amino acid positions 1 to 210 of SEQ ID NO. 70 and allelic variants of natural occurrence and / or splice thereof. "PRLR ECD" as used herein refers to the extracellular portion of PRLR represented by the aforementioned amino acids. In addition, the target human PRLR also covers mutated versions of the receptor, such as the activating mutation I146L described by Paul Kelly (Proc Natl Acad Sci US A.105 (38): 14533-14538,2008; and Oral Communication Turin, 2007) .
[00146] As used herein, the phrase "therapeutically effective amount" is meant to refer to an amount of therapeutic or prophylactic antibody that would be appropriate to elicit the desired therapeutic or prophylactic effect or response, including alleviating some or all of such symptoms. disease or reducing the predisposition to the disease, when administered according to the desired treatment regimen.
[00147] As used herein, an antibody "specifically binds to," is "for / from specific" or "specifically recognizes" an antigen (here, PRLR) if such an antibody is able to discriminate between such an antigen and one or more antigen reference (s), since the link specificity is not an absolute property, but a relative one. In its most general form (and when no definite reference is mentioned), "specific binding" is referring to the antibody's ability to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, according to a following methods. Such methods include, but are not limited to, western blot, ELISA, RIA, ECL, IRMA tests and peptide scans. For example, a standard ELISA assay can be performed. Counting can be performed by standard color development (for example secondary antibody with horseradish peroxide and tetramethyl benzidine with hydrogen peroxide). The reaction in certain wells is recorded by the optical density, for example, at 450 nm. Typical background (= negative reaction) can be 0.1 OD; typical positive reaction can be 1 OD. This means that the positive / negative difference can be more than 10 times. Typically, determination of binding specificity is performed not using a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or others.
[00148] However, "specific binding" can also refer to an antibody's ability to discriminate between the target antigen and one or more closely related antigen (s) that are used as reference points. In addition, "specific binding" can refer to an antibody's ability to discriminate between different parts of its target antigen, for example different domains, subdomains or regions of PRLR, such as epitopes in the N-terminal or C-terminal region of the ECD of PRLR, or between one or more fundamental amino acid residues or extensions of amino acid residues of the PRLR ECD.
[00149] "Affinity" or "binding affinity" KD is often determined by measuring the equilibrium association constant (ka) and the equilibrium dissociation constant (kd) and calculating the quotient from kd to ka (KD = kd / ka). The term "immunospecific" or "specifically ligand" means that the antibody binds to the PRLR or its ECD with a KD affinity of less than or equal to 10-6M (monovalent affinity). The term "high affinity" means that the KD that the antibody binds to PRLR or its ECD with a KD affinity of less than or equal to 10-7M (monovalent affinity). The antibody may have substantially greater affinity for the target antigen compared to other unrelated molecules. The antibody may also have substantially greater affinity for the target antigen compared to counterparts, for example at least 1.5 times, 2 times, 5 times, 10 times, 100 times, 10-3 times, 10-4 times, 10- 5 times , 10-6 times or greater affinity with the target antigen. Such affinities can be easily determined using conventional techniques, such as through equilibrium dialysis; using the BIAcore 2000 instrument, using the general procedures outlined by the manufacturer; through radioimmunoassay using the radiolabeled target antigen; or by another method known to the skilled craftsman. Affinity data can be analyzed, for example, by the method of Scatchard et al., Ann N.Y. Acad. ScL, 51: 660 (1949).
[00150] As used herein the phrase "antibodies antagonize prolactin-mediated signaling" is meant to refer to a blockade of prolactin receptor activation by the antibodies of the present invention that leads to complete inhibition of prolactin receptor-mediated signaling.
[00151] As used herein the phrase "antibodies compete to bind" is meant to refer to a competition between one antibody and a second antibody or more antibodies for binding to the prolactin receptor.
[00152] The term "antibody" is used in the broadest sense and includes fully assembled antibodies, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (for example, bispecific antibodies), antibody fragments that can bind to the antigen (for example, Fab ', F' (ab) 2, Fv, single chain antibodies, diabodies), camel bodies and recombinant peptides that comprise the above as long as they exhibit the desired biological activity. Antibodies can carry different constant domains (Fc domains) in their heavy chain, preferably derived from the IgG1, IgG2, or IgG4 isotypes (see below). Mutations to modify effector functions can be introduced. Amino acid residues in the Fc domain that play a dominant role in interactions with the complement protein C1q and Fc receptors have been identified and mutations that influence effector functions have been described (for a review see Labrijn et al., Current Opinion in Immunology 20 : 479-485, 2008). In particular, IgG1 aglycosylation can be achieved by mutating asparagine to alanine or asparagine to glutamine at amino acid position 297 which has been reported to abolish antibody-derived cell-mediated cytotoxicity (ADCC) (Sazinsky et al., Proc. Nat. Acad. Sci. Sci. 105 (51): 20169, 2008; Simmons et al., J. de Immunological Methods 263: 133-147, 2002). Replacement of lysine with alanine at position 322 leads to a reduction in ADCC and removal of complement-derived cytotoxicity (CDC), while simultaneous replacement of the two leucines at position 234 and 235 by alanines leads to avoidance of ADCC and CDC [Hezareh et al. , J. of Virology, 75 (24): 12161-12168, 2001]. In order to apply IgG4 isotypes as bivalent therapies in vivo having avidity, a modification such as the exchange of serine-to-proline in the "core hinge region" (Schuurman, J., et al. Immunology 97: 693- 698, 1999) can be introduced. The tendency of human IgG2 molecules to form heterogeneous covalent dimers can be avoided by switching one of the cysteines at position 127, 232 and 233 to serine (Allen et al., Biochemistry, 2009, 48 (17), pp. 3755-3766). An alternative format with reduced effector function may be the IgG2m4 format, derived from IgG2 that carries four alterations of specific IgG4-amino acid residues (An et al., MAbs 1 (6), 2009). Antibody fragments can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies and are described below. Non-limiting examples of monoclonal antibodies include murine, chimeric, humanized, human, and Human Engineered ™ immunoglobulins, antibodies, chimeric fusion proteins having sequences derived from immunoglobulins, or muteins or derivatives thereof, each described below. Multimers or aggregates of intact molecules and / or fragments, including chemically derivatized antibodies, are contemplated.
[00153] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, that is, the individual antibodies that comprise the population are identical except for possible naturally occurring mutations that may be secondary amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In addition, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant in the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by homogeneous culture, uncontaminated by other immunoglobulins with different specificities and characteristics.
[00154] The "monoclonal" modifier indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and will not be interpreted as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used can be made first by the hybridoma method described by Kohler et al., Nature, 256: 495 [1975, or can be made using recombinant DNA methods (see, for example, US Patent 4,816,567). The "monoclonal antibodies" can also be recombinant, chimeric, humanized, Human Engineered ™, Human, or antibody fragments, for example.
[00155] An "immunoglobulin" or "native antibody" is a tetrameric glycoprotein. In a naturally occurring immunoglobulin, each tetramer is composed of two identical pairs of polypeptide chains, each pair having a "light" (about 25 kDa) and a "heavy" chain (about 50-70 kDa). The amino-terminal portion of each chain includes a "variable" region of about 100 to 110 or more amino acids primarily responsible for recognizing the antigen. The carboxy-terminal portion of each chain defines a constant region primarily responsible for the effector function. Immunoglobulins can be assigned to different classes depending on the amino acid sequence of the constant domain of their heavy chains. Heavy chains are classified as mu (μ), delta (Δ), gamma (Y), alpha (a), and epsyl (ε), and define the antibody isotype as IgM, IgD, IgG, IgA, and IgE, respectively . Several of these can be further divided into subclasses or isotypes, for example IgG1, IgG2, IgG3, IgG4, IgAl and IgA2. Different isotypes have different effector functions; for example, IgG1 and IgG3 isotypes often have ADCC activity. Human light chains are classified as kappa (K) and lambda (Y) light chains. Within light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids. See, in general, Fundamental Immunology, Chap. 7 (Paul, W. ed., 2nd ed. Raven Press, N.Y. (1989)).
An "functional fragment" or "antibody antigen binding fragment" of an antibody / immunoglobulin here is defined as an antibody / immunoglobulin fragment (for example, a variable region of an IgG) that retains the region of antigen binding. An "antigen binding region" of an antibody is typically found in one or more hypervariable region (s) of an antibody, i.e., the CDR-1, 2, and / or 3 regions; however, variable "structural" regions can also play an important role in binding the antigen, such as providing a scaffold for CDRs. Preferably, the "antigen binding region" comprises at least amino acid residues 4 to 103 of the light variable chain (VL) and 5 to 109 of the heavy variable chain (VH), more preferably amino acid residues 3 to 107 of the VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains [amino acid positions 1 to 109 of VL and 1 to 113 of VH, while the numbering of amino acid positions occurs according to the Kabat database ( Johnson and Wu, Nucleic Acids Res., 2000, 28, 214-218] A preferred class of immunoglobulins for use in the present invention is IgG.
[00157] The term "hypervariable" region refers to the amino acid residues of the VH and VL variable domains of an antibody or functional fragment that are responsible for binding the antigen. The hypervariable region comprises amino acid residues from a "complementarity determining region" or CDR [i.e. residues 24-34 (LCDR1), 50 - 56 (LCDR2) and 88-97 (LCDR3) in the variable domain of the light chain and 29-36 (HCDR1), 48-66 (HCDR2) and 93-102 (HCDR3) in the variable domain of the heavy chain as described in Fig. 12] and / or those residues of a hypervariable loop [i.e. residues 26-32 (within LCDR1), 50-52 (within LCDR2) and 91-96 (within LCDR3) in the light chain variable domain and 26-32 (within HCDR1), 53 - 55 (within HCDR2) and 96- 101 (within HCDR3) in the heavy chain variable domain as described by Chothia et al., J. Mol. Biol. 196: 901-917 (1987)].
[00158] Non-limiting examples of antibody fragments include Fab, Fab ', F (ab') 2, Fv, domain antibody (dAb), fragments of the complementarity determining region (CDR), single chain antibodies (scFv ), single chain antibody fragments, diabody, tribody, tibody, minibody, linear antibody (Zapata et al., Protein Eng., 8 (10): 1057-1062 (1995)); recombinant chelating antibodies, triceps or bodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), an immunoglobulin fusion protein from the antigen binding domain, a camelized antibody, an antibody containing VHH, or muteins or their derivatives, and polypeptides containing at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide, such as a CDR sequence, as long as the antibody retains the desired biological activity; and multispecific antibodies formed from antibody fragments (CA K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag). An antibody other than a "bispecific" or "bifunctional" antibody is understood to have each of its identical binding sites. F (ab ') 2 or Fab can be engineered to minimize or completely remove the intermolecular disulfide interactions that occur between the CH1 and CL domains. Papain digestion of antibodies produces two identical antigen binding fragments, called "Fab" fragments, each with a single antigen binding site, and a residual "Fc" fragment whose name reflects its ability to crystallize easily. Pepsin treatment yields an F (ab ') 2 fragment that has two "Fv" fragments. An "Fv" fragment is the minimum antibody fragment containing a complete antigen recognition and binding site. This region consists of a dimer of a heavy chain variable domain and a light chain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three antigen-specific CDRs) has the ability to recognize and bind the antigen.
[00159] "Single chain Fv" or "sFv" or "scFv" antibody fragments comprise the VH and VL domains of the antibody, where these domains are present in a single polypeptide chain.
[00160] Preferably, the Fv polypeptide still comprises a polypeptide linker between the VH and VL domains that allows the Fv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, p. 269-315 (1994).
[00161] The Fab fragment also contains the light chain constant domain and the first heavy chain constant domain (CH1). Fab fragments differ from Fab 'fragments by adding some residues to the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation here for Fab 'where the cysteine residue (s) of the constant domains carry a free thiol group. F (ab ') 2 antibody fragments were originally produced as pairs of Fab' fragments having hinge cysteines between them.
[00162] "Structure" or FR residues are residues from variable domains other than residues from the hypervariable region.
[00163] The phrase "constant region" refers to the portion of the antibody molecule that confers effector functions.
[00164] The term "mutein" or "variant" can be used interchangeably and refers to the polypeptide sequence of an antibody containing at least one substitution, deletion, or insertion of amino acid in the variable region or the portion equivalent for the region variable, as long as the mutein or variant retains the desired binding affinity or biological activity.
[00165] Muteins can be substantially homologous or substantially identical to the parent antibody.
[00166] The term "derivative" refers to antibodies covalently modified by such techniques as ubiquitination, conjugation with therapeutic or diagnostic agents, labeling (for example, with radionuclides or various enzymes), covalent polymer binding such as pegylation (derivatization polyethylene glycol) and insertion or substitution by chemical synthesis of unnatural amino acids.
[00167] A "human" antibody or functional human antibody fragment is hereby defined as one that is not chimerical or "humanized" and not of (or in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A "synthetic human antibody" is defined herein as an antibody having a sequence derived, in whole or in part, in silico from synthetic sequences which are based on the analysis of known human antibody sequences. In silico design of a human antibody sequence or its fragment can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and inventing a polypeptide sequence that uses the data obtained from it. Another example of a human antibody or functional antibody fragment is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (i.e., such a library being based on antibodies taken from a natural human source). Examples of human antibodies include antibodies based on n-CoDeR as described by Carlsson and Soderlind Exp. Rev. Mol. Diagn. 1 (1), 102-108 (2001), Soderlin et al. Nat. Biotech. 18, 852-856 (2000) and U. S. patent 6,989,250.
[00168] A "humanized antibody" or functional humanized antibody fragment is defined here as one that is (i) derived from a non-human source (for example, a transgenic mouse that carries a heterologous immune system), whose antibody is with based on a human germline sequence; or (ii) grafted into the CDR, where the CDRs of the variable domain are of non-human origin, while one or more structures of the variable domain are of human origin and the constant domain (if any) is of human origin.
[00169] The phrase "chimeric antibody," as used herein, refers to an antibody containing a sequence derived from two different antibodies (see, for example, U. S. Patent 4,816,567) that typically originate from different species. More typically, chimeric antibodies comprise human and murine antibody fragments, in general human and mouse constant regions.
[00170] "Human Engineered ™" antibodies generated by altering the source sequence according to the methods set out in Studnicka et al., US Patent 5,766,886 such as the antibody represented by SEQ ID NOs 58, 61, 64, 67 and described in patent application WO08 / 022295.
[00171] An antibody of the invention can be derived from a library of recombinant antibody genes. The development of technologies to make repertoires of recombinant human antibody genes, and the display of antibody fragments encoded on the filamentous bacteriophage surface, provided a recombinant means for directly making and selecting human antibodies, which can also be applied to humanized, chimeric antibodies. , murine or mutein. Antibodies produced by phage technology are produced as antigen-binding fragments - usually Fv or Fab fragments - in bacteria and are thus devoid of effector functions. Effector functions can be introduced by one of two strategies: Fragments can either be engineered into full-length antibodies for expression in mammalian cells, or in bispecific antibody fragments with a second binding site capable of triggering an effector function. Typically, the Fd (VH-CH1) and light chain (VL-CL) fragment of the antibodies is cloned separately by chance by PCR and recombined in combinatorial phage display libraries that can then be selected to bind to a particular antigen. Fab fragments are expressed on the phage surface, that is, physically linked to the genes that encode them. Thus, selection of Fab by antigen binding coselects for Fab coding sequences, which can subsequently be amplified. Through several cycles of antigen binding and re-amplification, a procedure called panning, Fab specific for the antigen are enriched and finally isolated.
[00172] A variety of procedures have been described to derive human antibodies from phage display libraries. Such libraries can be constructed in a simple main structure to which several CDRs formed in vivo (ie, derived from human) are allowed to recombine as described by Carlsson and Soderlind Exp. Rev. Mol. Diagn. 1 (1), 102-108 (2001), Soderlin et al. Nat. Biotech. 18, 852-856 (2000) and U. S. patent 6,989,250. Alternatively, such an antibody library can be based on the amino acid sequences that have been designed in silico and have been encoded by nucleic acids that are synthetically created. In silico design of an antibody sequence is achieved, for example, by analyzing a human sequence database and designing a polypeptide sequence that uses the data obtained from it. Methods for designing and obtaining sequences created in silico are described, for example, in Knappik et al., J. Mol. Biol. (2000) 296: 57; Krebs et al., J. Immunol. Methods. (2001) 254: 67; and U. S. patent 6,300,064. For a review of phage display techniques, see WO08 / 022295 (Novartis).
[00173] Alternatively, an antibody of this invention can come from animals. Such an antibody can be humanized or Human Engenheired ™ summarized in WO08 / 022295 (Novartis); such an antibody can come from transgenic animals [see also WO08 / 022295 (Novartis)].
[00174] As used herein, different "forms" of antigen, for example PRLR, are hereby defined as different protein molecules that result from different translational and post-translational modifications, such as, but not limited to, differences in splicing primary transcription of the prolactin receptor, differences in glycosylation, and differences in post-translational proteolytic cleavage.
[00175] As used herein, the term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T cell receptor. Epitopic determinants usually consist of chemically active surface clusters of molecules such as amino acids or side chains of sugar and usually have three specific dimensional structural characteristics, as well as specific load characteristics. Two antibodies are said to "bind to the same epitope" if one antibody is shown to compete with the second antibody in a competitive binding assay, by any of the methods well known to those of skill in the art, and if preferably all of the epitope amino acids linked by the two antibodies.
[00176] The term "mature antibodies" or "mature antigen binding fragments" such as mature Fab variants include derivatives of an antibody or antibody fragment that exhibit stronger binding - that is, binding with increased affinity - to an antigen data such as the extracellular domain of the PRLR. Maturation is the process of identifying a small number of mutations within the six CDRs of an antibody or antibody fragment leading to this increase in affinity. The maturation process is the combination of molecular biology methods for introducing mutations in the antibody and screening to identify the improved binders. THERAPEUTIC METHODS
[00177] Therapeutic methods involve administering to a subject in need of a therapeutically effective amount of treatment for an antibody contemplated by the invention. A "therapeutically effective" amount is hereby defined as the amount of an antibody that is of an amount sufficient to block the proliferation of PRLR-positive cells in an area treated as a single dose or according to a dose regimen multiple, alone or in combination with still other agents, which leads to the relief of an adverse condition, even though the amount is toxicologically tolerable. The subject can be a human or non-human animal (for example, rabbit, rat, mouse, monkey or other lower order primate).
[00178] An antibody of the invention could be co-administered with known drugs, and in some circumstances the antibody can be modified. For example, an antibody could be conjugated to an immunotoxin or radioisotope to potentially also increase effectiveness.
[00179] Inventive antibodies can be used as a therapeutic tool or a diagnostic tool in a variety of situations where PRLR is undesirably highly expressed. Particularly suitable disorders and conditions for treatment with an antibody of the inventions are endometriosis, adenomyosis, non-hormonal female fertility contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper hair loss and normoprolactinemic , and co-treatment in combined hormonal therapy to inhibit proliferation of breast epithelial cells.
[00180] To treat any of the above disorders, pharmaceutical compositions for use according to the present invention can be formulated in a conventional manner using one or more physiologically acceptable vehicles or excipients. An antibody of the invention can be administered by any suitable means which can vary depending on the type of disorder being treated. Possible routes of administration include parenteral (e.g., intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous), intrapulmonary and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration. In addition, an antibody of the invention could be administered via pulse infusion, with, for example, decreasing the doses of the antibody. Preferably, dosing is given through injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. The amount to be administered will depend on a variety of factors such as the clinical symptoms, the individual's weight, whether other drugs are administered. The skilled artisan will recognize that the route of administration will vary, depending on the disorder or condition to be treated.
[00181] Determining a therapeutically effective amount of the new polypeptide according to this invention will largely depend on the characteristics of the particular patient, the route of administration, and the nature of the disorder being treated. General guidance can be found, for example, in the publications of the International Conference on Harmonization and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, p. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa .: Mack Pub. Co., 1990). More specifically, determining a therapeutically effective amount will depend on such factors as drug toxicity and efficacy. Toxicity can be determined using methods well known in the art and found in the previous references. Effectiveness can be determined using the same guidance along with the methods described below in the Examples. PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION
[00182] The present invention also relates to pharmaceutical compositions that may comprise PRLR antibodies, alone or in combination with at least one other agent, such as a stabilizing compound that can be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to a, saline, buffered saline, dextrose, and water. Any of these molecules can be administered alone to a patient, or in combination with other agents, drugs or hormones, in pharmaceutical compositions where it is mixed with pharmaceutically acceptable excipient (s) or vehicles. In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert.
[00183] The present invention also concerns the administration of pharmaceutical compositions. Such administration is carried out parenterally. Parenteral delivery methods include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine or intranasal administration. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers that comprise excipients and auxiliaries that facilitate the processing of the active compounds in preparations that can be used pharmaceutically. More details on techniques for formulation and administration can be found in the latest issue of Remington's Pharmaceutical Sciences (Ed. Maack Publishing Co, Easton, Pa.).
[00184] Pharmaceutical formulations for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. In addition, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow the preparation of highly concentrated solutions.
[00185] For topical or nasal administration, penetrants appropriate for the particular barrier to be penetrated are used in the formulation. Such penetrants are generally known in the art.
[00186] Parenteral administration also comprises parenteral delivery methods that also include intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, and intraventricular, intravenous, intraperitoneal, intrauterine, vaginal, or intranasal administration. KITS
[00187] The invention also relates to pharmaceutical packages and kits that comprise one or more containers filled with one or more of the ingredients of the above mentioned compositions of the invention. Associated with such container (s) may be a note in the form written by a government agency that regulates the manufacture, use or sale of pharmaceuticals or biological products, reflecting the agency's approval of the manufacture, use or sale of the product for administration human.
[00188] In another embodiment, the kits may contain DNA sequences that encode the antibodies of the invention. Preferably the DNA sequences encoding these antibodies are provided on a plasmid suitable for transfection and expression by a host cell. The plasmid can contain a promoter (often an inducible promoter) to regulate the expression of DNA in the host cell. The plasmid can also contain appropriate restriction sites to facilitate insertion of other DNA sequences into the plasmid to produce various antibodies. Plasmids can also contain numerous other elements to facilitate the cloning and expression of encoded proteins. Such elements are well known to those of skill in the art and include, for example, selectable markers, initiation codons, termination codons, and the like. MANUFACTURE AND STORAGE
[00189] The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, for example, by means of conventional mixing, dissolving, granulating, in dragees, spraying, emulsifying, encapsulating, capturing or lyophilizing processes.
[00190] The pharmaceutical composition can be supplied as a lyophilized powder in 1 mM-50 mM histidine, 0.1% -2% sucrose, 2% -7% mannitol at a pH range of 4.5 to 5 , 5 which is combined with buffer before use.
[00191] After the pharmaceutical compositions comprising a compound of the invention formulated in an acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PRLR antibodies, such a label would include quantity, frequency and method of administration. THERAPEUTICALLY EFFECTIVE DOSE
[00192] Pharmaceutical compositions suitable for use in the present invention include compositions in which the active ingredients are contained in an effective amount to achieve the intended purpose, i.e., treatment of a particular disease state characterized by expression of PRLR. The determination of an effective dose is well within the capacity of those skilled in the art.
[00193] For any compound, the therapeutically effective dose can be initially estimated in cell culture assays, for example, lymphoma cells, or in animal models, usually mice, rats, rabbits, dogs, pigs or monkeys. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
[00194] A therapeutically effective dose refers to that amount of protein or its antibodies, antagonists, or inhibitors that improve symptoms or condition. Therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, ED50 (the therapeutically effective dose in 50% of the population) and LD50 (the lethal dose in 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and can be expressed as the ratio, ED50 / LD50. Pharmaceutical compositions that exhibit a large therapeutic index are preferred. The data obtained from cell culture assays and animal studies are used in the formulation of a dosage range for human use. The dosage of such compounds is preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage varies within this range depending on the dosage form used, patient sensitivity, and the route of administration.
[00195] The exact dosage is chosen by the doctor in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active half or to maintain the desired effect. Additional factors that can be taken into account include the severity of the disease state, for example, the size and location of the endometriotic lesions; patient's age, weight and gender; diet, time and frequency of administration, drug combination (s), reaction sensitivities, and tolerance / response to therapy. Long-acting pharmaceutical compositions could be administered every 3 to 4 days, every week, or once every two weeks, or once within a month depending on the half-life and clearance rate of the particular formulation.
[00196] Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 2 g, depending on the route of administration. Guidance on particular dosages and delivery methods is provided in the literature. See US 4,657,760; US 5,206,344; or US 5,225,212. Those skilled in the art will employ different formulations for polynucleotides than for proteins or their inhibitors. Similarly, the release of polynucleotides or polypeptides will be specific to cells, conditions, particular locations, etc. Preferred specific activities for a radiolabeled antibody can range from 0.1 to 10 mCi / mg of protein (Riva et al., Clin. Cancer Res. 5: 3275s-3280s, 1999; Wong et al., Clin. Cancer Res. 6 : 3855-3863, 2000; Wagner et al., J. Med Nuclear. 43: 267-272, 2002).
[00197] The present invention is further described by the following examples. Examples are provided to illustrate the invention only with reference to specific embodiments. These exemplifications, illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.
[00198] All examples were performed using standard techniques that are well known and routine for those of skill in the technique, except where otherwise described in detail. Routine molecular biology techniques from the following examples can be performed as described in standard laboratory manuals, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed .; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. DESCRIPTION OF THE FIGURES
[00199] Figure 1: Expression of prolactin-mRNA (PRL-mRNA) (analyzed through real-time TaqMan PCR analysis) in human endometrium and lesions (ectopic tissue) of healthy women and women suffering from endometriosis.
[00200] Figure 2: Expression of prolactin-mRNA receptor (PRLR-mRNA) (analyzed by real-time TaqMan PCR analysis) in human endometrium and lesions (ectopic tissue) of healthy women and women suffering from endometriosis.
[00201] Figure 3: Northern blot analysis of PRLR gene expression in rat tissues. Gene expression of PRLR revealed high expression in the placenta and prostate.
[00202] Figure 4: Western blot analysis of PRLR expression in rat prostates treated with different hormones. Treatment of estradiol from intact rats and castration leads to an overload of PRLR protein in rat prostates while treatment of dihydrotestosterone from intact rats had no impact on PRLR expression in the prostate compared to vehicle treatment from intact animals.
[00203] Figure 5: Inhibition of proliferation of Ba / F (= Baf) cells activated by prolactin (stably expressing human PRLR) neutralizing PRLR antibodies and non-specific control antibodies. IC50 values were determined for the following antibodies in IgG1 format: 005-C04 (filled circles): 1.29 μg / ml = 8.6 nM; 006-H08 (empty circles): 0.15 μg / ml = 1 nM; HE06.642 (filled triangles): 0.34 μg / ml = 2.2 nM; 002-H06 (empty triangles): 0.54 μg / ml = 3.6 nM; 002-H08 (filled squares): 0.72 μg / ml = 4.8 nM; non-specific control antibody (empty squares): no inhibition of cell proliferation.
[00204] Figure 6: Inhibition of proliferation of mouse lymphoma cells induced by prolactin (NB2 cells) by neutralizing PRLR antibodies and non-specific control antibodies. The following IC50 values were determined: XHA06.642 (filled circles): 10 μg / ml = 67 nM; XHA06.983 (empty circles): no effect on the proliferation of rat lymphoma cells; non-specific control antibody (full triangle): no effect at 10 μg / ml.
[00205] Figure 7: Inhibition of prolactin-stimulated STAT5 phosphorylation in T47D cells by neutralizing PRLR antibodies and non-specific control antibody.
[00206] The non-specific control antibody (FITC) does not inhibit the phosphorylation of STAT5 in T47D cells. In contrast, the antibodies XHA06.642, 005-C04 (= IgG1 005-C04), and 006-H08 (= IgG1 006-H08) inhibit STAT5 phosphorylation in a dose-dependent manner in T47D cells.
[00207] Figure 8: Effects of neutralizing PRLR antibodies and non-specific controls on luciferase reporter gene prolactin-activated activity using HEK293 cells stably transfected with the human prolactin receptor (hPRLR) and transiently expressing the luciferase gene under control of lactogenic hormone response elements (LHREs). IC50 values were determined for the following antibodies in IgG1 format: 006-H08 (filled circles): 0.83 μg / ml = 5.5 nM; HE06.642 (empty circles): 0.63 μg / ml = 4.2 nM; non-specific control antibody (full triangle): no inhibition of luciferase activity.
[00208] Figure 9: Effects of neutralizing PRLR antibodies and nonspecific controls on luciferase reporter gene prolactin-activated activity using HEK293 cells stably transfected with the murine prolactin receptor (mPRLR) and transiently expressing the luciferase gene under control of lactogenic hormone response elements (LHREs). IC50 values were determined for the following IgG1 antibodies: 005-C04 (filled triangles): 0.45 μg / ml = 3 nM; XHA06.642 (filled circles):> 50 μg / ml> 333 nM, non-specific control antibody (empty circles): no inhibition of luciferase activity.
[00209] Figure 10: Inhibition of proliferation of Ba / F (= Baf) cells activated by prolactin (stably expressing the murine prolactin receptor) by neutralizing antibodies to the prolactin receptor and non-specific control antibodies. IC50 values were determined for the following IgG1-format antibodies: non-specific FITC antibody (full squares): no inhibition of cell proliferation; HE06.642 (filled circles):>> 30 μg / ml> 200 nM; 001-E06 (empty circles): 43.7 μg / ml = 291 nM; 001-D07 (filled triangles): 16.5 μg / ml = 110 nM; 005-C04 (empty triangles): 0.74 μg / ml = 4.9 nM.
[00210] Figure 11: Pregnancy rates and average litter size in female mice treated with phosphate buffered saline (= vehicle), non-specific control antibody (FITC IgG1) or neutralizing IgG1 antibody 005-C04 (= 005-C04 ). Pregnancy rates were 87.5% (females treated with vehicle), 75% (females treated with 10 mg / kg of non-specific antibody), 100% (females treated with 10 mg / kg of IgG1 005-C04), and 0 % (females treated with 30 mg / kg IgG1 005-C04). Average litter size was 10.9 animals (females treated with vehicle), 12.3 animals (females treated with 10 mg / kg of non-specific antibody), 13 animals (females treated with 10 mg / kg of IgG1 005-C04) and 0 animals (females treated with 30 mg / kg IgG1 005-C04).
[00211] Figure 12: Kabat numbering of the amino acid positions of the structure according to Johnson and Wu (Nucleic Acids Res. 2000, 28, 214-218).
[00212] Figure 13: Results of FACS analysis with selected anti-PRLR antibodies (005-C04, 001-E06, HE06642). Antibody binding was determined at a fixed concentration in HEK293 cells expressing for human PRLR and for mouse compared to the parental cell line not expressing PRLR.
[00213] Figure 14A: Litter weight gain during each postpartum day expressed as percentage of litter weight obtained on the postpartum day 1. Weight gain of the litters of untreated mothers (full circles), of mothers treated with 10 mg / kg of non-specific murine IgG2a antibody (empty circles), and of mothers treated with the neutralizing antibody 005-C04 containing constant domains of murine IgG2a (= IgG2a 005-C04) at 10 mg / kg (filled triangles) and at 30 mg / kg (empty triangles) are shown. The arrows indicate days on which the antibody injection was performed. There is a significant reduction in the weight gain of the litters of mothers treated with 30 mg / kg of IgG2a 005-C04 from postpartum day 8 onwards.
[00214] Figure 14B: Incremental weight gain of the litter expressed each day as percentage of litter weight on the postpartum day 1. Results of the litters of untreated mothers (full circles), of the mothers treated with 10 mg / kg of murine IgG2a non-specific antibody (empty circles), from mothers treated with the neutralizing antibody 005-C04 containing constant domains of murine IgG2a (= IgG2a 005-C04) at 10 mg / kg (filled triangles) and 30 mg / kg ( empty triangles) are shown. Basically, Figure 14A shows the slope of the graphs shown in Figure 14A. Daily weight gain in the litters of untreated mothers and mothers treated with 10 mg / kg of non-specific antibody fluctuates 30% of the litter weight around the postpartum day 1. In contrast, the treatment of mothers with 30 mg / kg IgG2a 005-C04 leads to a significant reduction in weight gain from day 7 onwards (* p <0.05; *** p <0.005 vs. litters of mothers treated with non-specific antibody) while treatment with 10 mg / kg of IgG2a 005-C04 leads to a significant reduction in daily weight gain from day 11 onwards (p <0.05 vs. litters of mothers treated with non-specific antibody). The arrows indicate days of application of the antibody.
[00215] Figure 14C: Histological sections of the mammary glands of lactating mothers. Mammary glands of untreated mothers or mothers treated with non-specific antibody are filled with milk production ducts. In contrast, involution of the mammary gland, confirmed by the appearance of islands of fat (black arrows), is induced in a dose-dependent manner by the neutralizing antibody of IgG2a 005-C04.
[00216] Figure 14D: Expression of milk protein in mammary glands of lactating mothers. Expression of casein beta milk proteins (Csn-2), acid whey protein (WAP), and IGF-1 is reduced in a dose-dependent manner in mothers treated with neutralizing PRLR IgG2a 005-C04 antibody, but not with antibodies non-specific. Gene expression was normalized in the expression of the TATA box-binding protein (TBP).
[00217] Figure 15A: Formation of lateral branches and alveolar structures in a hyperprolactinemic mouse model of benign breast disease. The neutralizing PRLR antibody IgG1 005-C04 (= 005-C04) inhibits lateral branching and the formation of alveolar structures equal to 10 and 30 mg / kg in mice that received a pituitary isograft.
[00218] Figure 15B: Extension of epithelial hyperplasia and epithelial cell proliferation in a hyperprolactinemic mouse model of benign breast disease. Some BrdU-positive cells are marked with white arrows. The neutralizing PRLR antibody IgG1 005-C04 (= 005-C04) blocks epithelial hyperplasia and the proliferation of epithelial cells in the mammary gland.
[00219] Figure 15C: Extension of STAT5 phosphorylation in a hyperprolactinemic mouse model of benign breast disease. Some phospho-STAT5-positive cells are indicated by white arrows. The neutralizing PRLR antibody IgG1 005-C04 (= 005-C04) completely blocks STAT5 phosphorylation when applied at a dosage of 30 mg / kg.
[00220] Figure 16: Inhibition of prostate growth by the neutralizing PRLR antibody 005-C04 containing constant domains of murine IgG2a (= IgG2a 005-C04). Pituitary isograft stimulates prostate growth compared to untreated pseudo-operated mice. Treatment with neutralizing antibodies to PRLR at doses of 10 mg / kg and at doses of 30 mg / kg inhibits prostate growth (*** p <0.005 vs. untreated, pseudo-operated mice).
[00221] Figure 17: Neutralizing PRLR antibodies stimulate hair growth in the presence of hyperprolactinemia. Photographs were taken three weeks after pituitary isograft (and scraping) of male mice used in the experiments described in Example 17 and Figure 16. Hyperprolactinemia inhibits hair regrowth in the shaved areas. Neutralizing PRLR antibodies, but not nonspecific antibodies, stimulate hair regrowth under hyperprolactinemic conditions at doses of 10 and 30 mg / kg of 005-C04 (= IgG2a 005-C04).
[00222] Figure 18: Neutralizing PRLR antibodies but not nonspecific antibodies stimulate hair regrowth in shaved areas in male and female hyper and normoprolactinemic mice (Example 18). Neutralizing PRLR antibodies are therefore suitable for the treatment of hair loss under normal and hyperprolactinemic conditions in men (Figure 18 B) and women (Figure 18A).
[00223] Figure 19: Neutralizing PRLR antibodies but not nonspecific control antibodies inhibit the increased proliferation of epithelial cells in the mammary gland after combined hormone therapy, that is, combined estrogen plus progestin therapy.
[00224] The absolute number of proliferative ductal epithelial cells within 4 cross sections of the mammary gland was evaluated and the averages are described as horizontal bars within the figure. Proliferation of epithelial cells in vehicle-treated ovariectomized mice is quite low (mean = 0). Treatment with estradiol leads to some stimulation of epithelial cell proliferation (mean = 9), maximum mammary epithelial cell proliferation is observed under estrogen plus progesterone treatment (mean = 144). Treatment with 005-C04 neutralizing antibody prolactin receptor (mean = 84 after treatment with 10 mg / kg 005-C04; mean = 27 after treatment with 30 mg / kg 005-C04) but not with non-specific control antibody (mean = 154) leads to a dose-dependent decrease in the proliferation of mammary epithelial cells almost back to estradiol levels only.
[00225] PRLR neutralizing antibodies are therefore suitable for treating increased proliferation of breast epithelial cells under combined hormonal therapy, i.e. treatment of estradiol plus progesterone.
[00226] Figure 20: PRLR neutralizing antibodies but non-specific control antibodies inhibit internal endometriosis in mice. The results are described as disease counts as described in Example 20. The average disease count for each experimental group is indicated as a horizontal bar. Normoprolactinemic mice develop internal endometriosis to some extent (mean disease count = 0.25). Hyperprolactinemia due to the pituitary isograft intensifies the disease count and more animals suffer from the disease (mean disease count = 2.5). While treatment with 30 mg / kg of non-specific antibody once (mean score = 2.5) or twice (mean score = 2) per week had no influence on the disease, treatment with specific neutralizing antibodies shows a dose decrease -dependent on the number of sick animals; the average disease count in all cases where the specific antibody was used was zero. Notably, all animals receiving 10 or 30 mg / kg of specific antibody twice a week are completely cured and their disease count was significantly lower than that of normoprolactinemic mice. Neutralizing PRLR antibodies are therefore suitable for treating internal endometriosis (= adenomyosis uteri) and external endometriosis in women.
[00227] FIGURE 21: Binding tests of mature Fab 006-H08 variants using homogeneous time-resolved fluorescence assay (HTRF):
[00228] E. coli supernatants containing Fab were tested for binding to the extracellular domain of human PRLR through competition with the 006-H08 IgG1 molecules. The figure illustrates the connection of the Fab variants as a bar diagram. Signal intensities (at 665 nM) at five different incubation times are given on the y axis, the names of the Fab variants on the x axis. Lower signals compared to the control Fab 006-H08 at a given time point indicate improved binding to the PRLR. All of the Fabs listed in Part 1 represent improved binders, while in Part 2, improved binders are shown as well as some non-improved binders.
[00229] SEQ ID NO: 1 represents amino acid sequence of HCDR1, 006-H08
[00230] SEQ ID NO: 2 represents amino acid sequence of HCDR1, 002-H06
[00231] SEQ ID NO: 3 represents amino acid sequence of HCDR1, 002-H08
[00232] SEQ ID NO: 4 represents amino acid sequence of HCDR1, 006-H07
[00233] SEQ ID NO: 5 represents amino acid sequence of HCDR1, 001-E06
[00234] SEQ ID NO: 6 represents amino acid sequence of HCDR1, 005-C04
[00235] SEQ ID NO: 7 represents amino acid sequence of HCDR2, 006-H08
[00236] SEQ ID NO: 8 represents amino acid sequence of HCDR2, 002-H06
[00237] SEQ ID NO: 9 represents amino acid sequence of HCDR2, 002-H08
[00238] SEQ ID NO: 10 represents amino acid sequence of HCDR2, 006-H07
[00239] SEQ ID NO: 11 represents amino acid sequence of HCDR2, 001-E06
[00240] SEQ ID NO: 12 represents amino acid sequence of HCDR2, 005-C04
[00241] SEQ ID NO: 13 represents amino acid sequence of HCDR3, 006-H08, 002-H06
[00242] SEQ ID NO: 14 represents amino acid sequence of HCDR3, 002-H08
[00243] SEQ ID NO: 15 represents amino acid sequence of HCDR3, 006-H07
[00244] SEQ ID NO: 16 represents amino acid sequence of HCDR3, 001-E06
[00245] SEQ ID NO: 17 represents amino acid sequence of HCDR3, 005-C04
[00246] SEQ ID NO: 18 represents amino acid sequence of LCDR1, 006-H08
[00247] SEQ ID NO: 19 represents amino acid sequence of LCDR1, 002-H06
[00248] SEQ ID NO: 20 represents amino acid sequence of LCDR1, 002-H08
[00249] SEQ ID NO: 21 represents amino acid sequence of LCDR1, 006-H07
[00250] SEQ ID NO: 22 represents amino acid sequence of LCDR1, 001-E06
[00251] SEQ ID NO: 23 represents amino acid sequence of LCDR1, 005-C04
[00252] SEQ ID NO: 24 represents amino acid sequence of LCDR2, 006-H08, 002-H08
[00253] SEQ ID NO: 25 represents amino acid sequence of LCDR2, 002-H06
[00254] SEQ ID NO: 26 represents amino acid sequence of LCDR2, 006-H07
[00255] SEQ ID NO: 27 represents amino acid sequence of LCDR2, 001-E06
[00256] SEQ ID NO: 28 represents amino acid sequence of LCDR2, 005-C04
[00257] SEQ ID NO: 29 represents amino acid sequence of LCDR3, 006-H08
[00258] SEQ ID NO: 30 represents amino acid sequence of LCDR3, 002-H06, 001-E06
[00259] SEQ ID NO: 31 represents amino acid sequence of LCDR3, 002-H08
[00260] SEQ ID NO: 32 represents amino acid sequence of LCDR3, 006-H07
[00261] SEQ ID NO: 33 represents amino acid sequence of LCDR3, 005-C04
[00262] SEQ ID NO: 34 represents VH amino acid sequence, 006-H08
[00263] SEQ ID NO: 35 represents VH amino acid sequence, 002-H06
[00264] SEQ ID NO: 36 represents VH amino acid sequence, 002-H08
[00265] SEQ ID NO: 37 represents amino acid sequence of VH, 006-H07
[00266] SEQ ID NO: 38 represents VH amino acid sequence, 001-E06
[00267] SEQ ID NO: 39 represents amino acid sequence of VH, 005-C04
[00268] SEQ ID NO: 40 represents amino acid sequence of VL, 006-H08
[00269] SEQ ID NO: 41 represents amino acid sequence of VL, 002-H06
[00270] SEQ ID NO: 42 represents amino acid sequence of VL, 002-H08
[00271] SEQ ID NO: 43 represents amino acid sequence of VL, 006-H07
[00272] SEQ ID NO: 44 represents amino acid sequence of VL, 001-E06
[00273] SEQ ID NO: 45 represents amino acid sequence of VL, 005-C04
[00274] SEQ ID NO: 46 represents VH nucleic acid sequence, 006-H08
[00275] SEQ ID NO: 47 represents VH nucleic acid sequence, 002-H06
[00276] SEQ ID NO: 48 represents VH nucleic acid sequence, 002-H08
[00277] SEQ ID NO: 49 represents VH nucleic acid sequence, 006-H07
[00278] SEQ ID NO: 50 represents VH nucleic acid sequence, 001-E06
[00279] SEQ ID NO: 51 represents VH nucleic acid sequence, 005-C04
[00280] SEQ ID NO: 52 represents nucleic acid sequence VL, 006-H08
[00281] SEQ ID NO: 53 represents nucleic acid sequence VL, 002-H06
[00282] SEQ ID NO: 54 represents nucleic acid sequence VL, 002-H08
[00283] SEQ ID NO: 55 represents nucleic acid sequence VL, 006-H07
[00284] SEQ ID NO: 56 represents nucleic acid sequence VL, 001-E06
[00285] SEQ ID NO: 57 represents nucleic acid sequence VL, 005-C04
[00286] SEQ ID NO: 58 represents amino acid sequence of VH, HE06642, Novartis (WO2008 / 22295)
[00287] SEQ ID NO: 59 represents amino acid sequence of VH, XHA06642, Novartis (WO2008 / 22295)
[00288] SEQ ID NO: 60 represents amino acid sequence of VH, XHA06983, Novartis (WO2008 / 22295)
[00289] SEQ ID NO: 61 represents amino acid sequence of VL, HE06642
[00290] SEQ ID NO: 62 represents VL amino acid sequence, XHA06642 Novartis (WO2008 / 22295)
[00291] SEQ ID NO: 63 represents VL amino acid sequence, XHA06983 Novartis (WO2008 / 22295)
[00292] SEQ ID NO: 64 represents VH nucleic acid sequence, HE06642
[00293] SEQ ID NO: 65 represents VH nucleic acid sequence, XHA06642 Novartis (WO2008 / 22295)
[00294] SEQ ID NO: 66 represents VH nucleic acid sequence, XHA06983 Novartis (WO2008 / 22295)
[00295] SEQ ID NO: 67 represents nucleic acid sequence VL, HE06642
[00296] SEQ ID NO: 68 represents nucleic acid sequence VL, XHA06642, Novartis (WO2008 / 22295)
[00297] SEQ ID NO: 69 represents nucleic acid sequence VL, XHA06983, Novartis (WO2008 / 22295)
[00298] SEQ ID NO: 70 represents human ECD_PRLR, amino acid position 1 - 210, S1 domain 1-100 (construction of S1 1- 102 domain), S2 domain 101-210
[00299] SEQ ID NO: 71 represents the human CDS ECD_PRLR, nucleotide position 1-630
[00300] SEQ ID NO: 72 represents murine ECD_PRLR, amino acid position 1 - 210
[00301] SEQ ID NO: 73 represents the murine CDS ECD_PRLR, nucleotide position 1-630
[00302] SEQ ID NO: 74: represents HCDR2, mature variants of 006-H08, amino acid sequence
[00303] SEQ ID NO: 75 represents HCDR2, mature variants of 006-H08, amino acid sequence
[00304] SEQ ID NO: 76 represents HCDR2, mature variants of 006-H08, amino acid sequence
[00305] SEQ ID NO: 77 represents HCDR2, mature variants of 006-H08, amino acid sequence
[00306] SEQ ID NO: 78 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00307] SEQ ID NO: 79 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00308] SEQ ID NO: 80 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00309] SEQ ID NO: 81 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00310] SEQ ID NO: 82 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00311] SEQ ID NO: 83 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00312] SEQ ID NO: 84 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00313] SEQ ID NO: 85 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00314] SEQ ID NO: 86 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00315] SEQ ID NO: 87 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00316] SEQ ID NO: 88 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00317] SEQ ID NO: 89 represents LCDR1, mature variants of 006-H08, amino acid sequence
[00318] SEQ ID NO: 90 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00319] SEQ ID NO: 91 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00320] SEQ ID NO: 92 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00321] SEQ ID NO: 93 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00322] SEQ ID NO: 94 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00323] SEQ ID NO: 95 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00324] SEQ ID NO: 96 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00325] SEQ ID NO: 97 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00326] SEQ ID NO: 98 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00327] SEQ ID NO: 99 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00328] SEQ ID NO: 100 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00329] SEQ ID NO: 101 represents LCDR3, mature variants of 006-H08, amino acid sequence
[00330] SEQ ID NO: 143 represents VH, 006-H08-12-2, amino acid sequence
[00331] SEQ ID NO: 144 represents VH, 006-H08-13-2, amino acid sequence
[00332] SEQ ID NO: 145 represents VH, 006-H08-13-6-1, amino acid sequence
[00333] SEQ ID NO: 146 represents VH, 006-H08-14-6-0, amino acid sequence
[00334] SEQ ID NO: 147 represents VH, 006-H08-15-5, amino acid sequence
[00335] SEQ ID NO: 148 represents VH, 006-H08-19-1, amino acid sequence
[00336] SEQ ID NO: 149 represents VH, 006-H08-29-1, amino acid sequence
[00337] SEQ ID NO: 150 represents VH, 006-H08-32-2, amino acid sequence
[00338] SEQ ID NO: 151 represents VH, 006-H08-33-0, amino acid sequence
[00339] SEQ ID NO: 152 represents VH, 006-H08-33-16-0, amino acid sequence
[00340] SEQ ID NO: 153 represents VH, 006-H08-35-17-1, amino acid sequence
[00341] SEQ ID NO: 154 represents VH, 006-H08-35-17-4, amino acid sequence
[00342] SEQ ID NO: 155 represents VH, 006-H08-35-1, amino acid sequence
[00343] SEQ ID NO: 156 represents VH, 006-H08-36-17-0, amino acid sequence
[00344] SEQ ID NO: 157 represents VH, 006-H08-37-19-0, amino acid sequence
[00345] SEQ ID NO: 158 represents VH, 006-H08-39-7, amino acid sequence
[00346] SEQ ID NO: 159 represents VH, 006-H08-48-5, amino acid sequence
[00347] SEQ ID NO: 160 represents VH, 006-H08-53-27-0, amino acid sequence
[00348] SEQ ID NO: 161 represents VH, 006-H08-59-30-0, amino acid sequence
[00349] SEQ ID NO: amino acid sequence 162 represents VH, 006-H08-63-32-4,
[00350] SEQ ID NO: amino acid sequence 163 represents VH, 006-H08-65-33-2,
[00351] SEQ ID NO: amino acid sequence 164 represents VH, 006-H08-68-35-2,
[00352] SEQ ID NO: 165 represents VL, 006-H08-12-2, amino acid sequence
[00353] SEQ ID NO: 166 represents VL, 006-H08-13-2, amino acid sequence
[00354] SEQ ID NO: 167 represents VL, 006-H08-13-6-1, amino acid sequence
[00355] SEQ ID NO: 168 represents VL, 006-H08-14-6-0, amino acid sequence
[00356] SEQ ID NO: 169 represents VL, 006-H08-15-5, amino acid sequence
[00357] SEQ ID NO: 170 represents VL, 006-H08-19-1, amino acid sequence
[00358] SEQ ID NO: 171 represents VL, 006-H08-29-1, amino acid sequence
[00359] SEQ ID NO: 172 represents VL, 006-H08-32-2, amino acid sequence
[00360] SEQ ID NO: 173 represents VL, 006-H08-33-0, amino acid sequence
[00361] SEQ ID NO: amino acid sequence 174 represents VL, 006-H08-33-16-0,
[00362] SEQ ID NO: 175 represents VL, 006-H08-35-17-1, amino acid sequence
[00363] SEQ ID NO: 176 represents VL, 006-H08-35-17-4, amino acid sequence
[00364] SEQ ID NO: 177 represents VL, 006-H08-35-1, amino acid sequence
[00365] SEQ ID NO: 178 represents VL, 006-H08-36-17-0, amino acid sequence
[00366] SEQ ID NO: 179 represents VL, 006-H08-37-19-0, amino acid sequence
[00367] SEQ ID NO: 180 represents VL, 006-H08-39-7, amino acid sequence
[00368] SEQ ID NO: 181 represents VL, 006-H08-48-5, amino acid sequence
[00369] SEQ ID NO: 182 represents VL, 006-H08-53-27-0, amino acid sequence
[00370] SEQ ID NO: amino acid sequence 183 represents VL, 006-H08-59-30-0,
[00371] SEQ ID NO: amino acid sequence 184 represents VL, 006-H08-63-32-4,
[00372] SEQ ID NO: amino acid sequence 185 represents VL, 006-H08-65-33-2,
[00373] SEQ ID NO: amino acid sequence 186 represents VL, 006-H08-68-35-2,
[00374] SEQ ID NO: 331 represents VH, 006-H08-12-2, nucleic acid sequence
[00375] SEQ ID NO: 332 represents VH, 006-H08-13-2, nucleic acid sequence
[00376] SEQ ID NO: 333 represents VH, 006-H08-13-6-1, nucleic acid sequence
[00377] SEQ ID NO: 334 represents VH, 006-H08-14-6-0, nucleic acid sequence
[00378] SEQ ID NO: 335 represents VH, 006-H08-15-5, nucleic acid sequence
[00379] SEQ ID NO: 336 represents VH, 006-H08-19-1, nucleic acid sequence
[00380] SEQ ID NO: 337 represents VH, 006-H08-29-1, nucleic acid sequence
[00381] SEQ ID NO: 338 represents VH, 006-H08-32-2, nucleic acid sequence
[00382] SEQ ID NO: 339 represents VH, 006-H08-33-0, nucleic acid sequence
[00383] SEQ ID NO: 340 represents VH, 006-H08-33-16-0, nucleic acid sequence
[00384] SEQ ID NO: 341 represents VH, 006-H08-35-17-1, nucleic acid sequence
[00385] SEQ ID NO: 342 represents VH, 006-H08-35-17-4, nucleic acid sequence
[00386] SEQ ID NO: 343 represents VH, 006-H08-35-1, nucleic acid sequence
[00387] SEQ ID NO: 344 represents VH, 006-H08-36-17-0, nucleic acid sequence
[00388] SEQ ID NO: 345 represents VH, 006-H08-37-19-0, nucleic acid sequence
[00389] SEQ ID NO: 346 represents VH, 006-H08-39-7, nucleic acid sequence
[00390] SEQ ID NO: 347 represents VH, 006-H08-48-5, nucleic acid sequence
[00391] SEQ ID NO: 348 represents VH, 006-H08-53-27-0, nucleic acid sequence
[00392] SEQ ID NO: 349 represents VH, 006-H08-59-30-0, nucleic acid sequence
[00393] SEQ ID NO: 350 represents VH, 006-H08-63-32-4, nucleic acid sequence
[00394] SEQ ID NO: 351 represents VH, 006-H08-65-33-2, nucleic acid sequence
[00395] SEQ ID NO: 352 represents VH, 006-H08-68-35-2, nucleic acid sequence
[00396] SEQ ID NO: 353 represents VL, 006-H08-12-2, nucleic acid sequence
[00397] SEQ ID NO: 354 represents VL, 006-H08-13-2, nucleic acid sequence
[00398] SEQ ID NO: 355 represents VL, 006-H08-13-6-1, nucleic acid sequence
[00399] SEQ ID NO: 356 represents VL, 006-H08-14-6-0, nucleic acid sequence
[00400] SEQ ID NO: 357 represents VL, 006-H08-15-5, nucleic acid sequence
[00401] SEQ ID NO: 358 represents VL, 006-H08-19-1, nucleic acid sequence
[00402] SEQ ID NO: 359 represents VL, 006-H08-29-1, nucleic acid sequence
[00403] SEQ ID NO: 360 represents VL, 006-H08-32-2, nucleic acid sequence
[00404] SEQ ID NO: 361 represents VL, 006-H08-33-0, nucleic acid sequence
[00405] SEQ ID NO: 362 represents VL, 006-H08-33-16-0, nucleic acid sequence
[00406] SEQ ID NO: 363 represents VL, 006-H08-35-17-1, nucleic acid sequence
[00407] SEQ ID NO: 364 represents VL, 006-H08-35-17-4, nucleic acid sequence
[00408] SEQ ID NO: 365 represents VL, 006-H08-35-1, nucleic acid sequence
[00409] SEQ ID NO: 366 represents VL, 006-H08-36-17-0, nucleic acid sequence
[00410] SEQ ID NO: 367 represents VL, 006-H08-37-19-0, nucleic acid sequence
[00411] SEQ ID NO: 368 represents VL, 006-H08-39-7, nucleic acid sequence
[00412] SEQ ID NO: 369 represents VL, 006-H08-48-5, nucleic acid sequence
[00413] SEQ ID NO: 370 represents VL, 006-H08-53-27-0, nucleic acid sequence
[00414] SEQ ID NO: 371 represents VL, 006-H08-59-30-0, nucleic acid sequence
[00415] SEQ ID NO: 372 represents VL, 006-H08-63-32-4, nucleic acid sequence
[00416] SEQ ID NO: 373 represents VL, 006-H08-65-33-2, nucleic acid sequence
[00417] SEQ ID NO: 374 represents VL, 006-H08-68-35-2, nucleic acid sequence EXAMPLES EXAMPLE 1 ISOLATION OF SPECIFIC ANTIBODIES TO THE TARGET OF HUMAN ANTIBODY DISPLAY LIBRARIES
[00418] To isolate a panel of antibodies capable of neutralizing human PRLR activity, three human antibody phage display libraries, expressing Fab and scFv fragments, were investigated in parallel. The target used for library panning was the soluble extracellular domain (ECD) of the prolactin receptor representing amino acids 25-234 of the human prolactin receptor, prepared as described above in WO08 / 022295 (Novartis). Alternative targets were the CD-terminal PRLR ECD linked to six histidines or to a human IgG1-Fc domain via the linker with the amino acid sequence "isoleucine-glutamate-glycine-arginine-methionine-aspartate".
[00419] Selection of specific antibodies to the phage display target was performed according to the methods described by Marks et al. (Methods Mol Bol. 248: 161-76, 2004). Briefly, the phage display library was incubated with 50 pmols of biotinylated ECD at room temperature for 1 h and the complex formed was then captured using 100 μl of streptavidin bead suspension (Dynabeads® M-280 Streptavidin, Invitrogen). Non-specific phages were removed by washing the beads with washing buffer (PBS + 5% Milk). Bound phage were eluted with 0.5 ml of 100 nM Triethylamine (TEA) and immediately neutralized by adding an equal volume of 1M TRIS-Cl pH 7.4. General background of the eluted phages was used to infect E. coli cells. of TG1 that grow in the log phase, and the phagemid was saved as described (Methods Mol Biol. 248: 161-76, 2004). Selection was repeated for a total of three cycles. Simple colonies were screened from TG1 cells infected with phage eluted from the third panning cycle for binding activity in an ELISA assay. Briefly, the simple colonies obtained from the infected TG1 cell were used with eluted phage to inoculate the media in the 96-well plates.
[00420] Microcultures were grown at an OD600 = 0.6 in which soluble antibody fragment spot expression was induced by adding 1 mM IPTG following culture overnight in a shaker incubator at 30 ° C. The bacteria were spun and the periplasmic extract was prepared and used to detect the binding activity of the antibody in immobilized ECD in the 96-well microplate (96-well flat bottom plates Immunosorb, Nunc) following the standard ELISA protocol provided by the manufacturer of the microplate.
[00421] The affinities of anti-prolactin receptor (PRLR) antibodies to bind to the recombinant extracellular domain (ECD) were estimated using Biacore® 2000 and used for antibody affinity classification. EXAMPLE 2 QUANTITATIVE ANALYSIS OF THE EXPRESSION OF THE PROLACTIN GENE AND THE PROLACTIN RECEPTOR THROUGH REAL-TIME TAQMAN CRP ANALYSIS IN EUCTOTIC AND ECTOPIC ENDOMETRIOTIC INJURIES OF HEALTHY PATIENTS AND CONTROLS
[00422] Taqman PCR analysis in real time was performed using the ABI Prism 7700 Sequence Detector System according to the manufacturer's instructions (PE Applied Biosystems) and as described in Endocrinolgy 2008, 149 (8): 3952-3959 ) and known to the field expert. The relative expression levels of PRL and PRLR were normalized for cyclophilin expression. We analyzed the expression of PRL and PRLR in the endometrium of healthy women and in endometrial and endometriotic lesions of patients using real-time Taqman quantitative PCR analysis. The expression of prolactin and its receptor was clearly overloaded in endometriotic lesions compared to healthy endometrium or patient-derived endometrium.
[00423] The results are shown in Figures 1 and 2.
[00424] These findings imply that autocrine prolactin signaling plays a role in the development and maintenance of endometriosis and adenomyosis uteri (internal endometriosis, a form of endometriosis restricted to the uterus. EXAMPLE 3 ANALYSIS OF PROLACTIN RECEPTOR EXPRESSION IN HUMAN TISSUE TISSUES DE NORTHERN BLOT
[00425] RNA was isolated from different rat tissues and transferred to a nylon membrane after gel electrophoresis. The membranes were successively hybridized with radioactive labeled cDNAs to the mouse prolactin or β-actin receptor (as a charge control), washed, and exposed to the film. The bands correspond to the mRNAs for the rat prolactin and β-actin receptor. The results shown in Figure 3 indicate a strong expression of the prolactin receptor in the placenta, prostate, ovary and adrenal gland. EXAMPLE 4 REGULATION OF PROLACTIN RECEPTOR PROTEIN EXPRESSION IN RAT PROSTATE - INFLUENCE OF CASTRATION AND HORMONAL TREATMENTS
[00426] The rats were either castrated or remained intact. The intact animals were treated daily for 14 days with vehicle (intact), DHT (3 mg / kg), or E2 (0.4 mg / kg). Then, the prostates were isolated from the animals of all treatment groups and protein extracts were prepared. Protein extracts were separated by gel electrophoresis and transferred to a membrane. The prolactin receptor was detected using the commercially available antibody MA610 (Santa Cruz Biotechnlogy). The results are shown in Figure 4 and indicate the hormonal regulation of the prolactin receptor in the rat prostate. EXAMPLE 5 INHIBITION OF PROLIFERATION INDUCED BY PROLACTIN FROM BAF3 CELLS (STABLE TRANSFECTED WITH THE HUMAN PROLACTIN RECEPTOR), PROLACTIN RECEPTOR NEUTRALIZING ANTIBODIES AND NON-SPECIFIC CONTROL ANTIBODIES
[00427] To analyze the in vitro efficacy of neutralizing PRLR antibodies, inhibition of prolactin-activated cell proliferation of BaF3 cells was used. The cells were stably transfected with human PRLR and were usually cultured in RPMI containing 2 mM glutamine in the presence of 10% FCS and 10 ng / ml human prolactin. After six hours of deprivation, cells were seeded in 96-well plates at a density of 10,000 cells per well in prolactin-free medium containing 1% FCS. The cells were stimulated with 20 ng / ml of prolactin and matched with increasing doses of neutralizing PRLR antibodies for two days. Cell proliferation was analyzed using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). Dose-response curves for the inhibition of cell growth stimulated by prolactin were generated and the IC 50 values were calculated. As a negative control, stimulation with a non-specific control antibody was used.
[00428] Dose-response curves and IC50 values are described in Figure 5. The non-specific antibody did not inhibit the proliferation of BaF cells stably expressing human PRLR, while specific antibodies blocked cell proliferation and showed potencies many different. Neutralizing antibody 006-H08 showed the highest potency in this reading paradigm. EXAMPLE 6 PROLIFERATION IN PROLIFERATION OF PROLACTIN-INDUCED MOUSE LYMPHOMA CELLS THROUGH SPECIFIC AND NON-SPECIFIC ANTIBODIES
[00429] The in vitro efficacy of neutralizing PRLR antibodies was also tested using inhibition of prolactin-dependent rat lymphoma cell proliferation (Nb2-11 cells). Nb2-11 cells were usually grown in RPMI containing 10% FCS and 10% horse serum. Before starting cell growth assays, cells were grown for 24 hours in the same medium containing 1% FCS instead of 10% FCS. Then, the cells were seeded in 96-well plates in FCS-free medium at a density of 10,000 cells per well. The cells were stimulated with 10 ng / ml of human prolactin in the presence or absence of increasing doses of neutralizing PRLR antibodies or control antibodies for 2 days. Then cell proliferation was assessed using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). Dose-response curves and IC 50 values are described in Figure 6. The non-specific antibody and XHA06.983 antibody that does not bind to the rat PRLR did not block the proliferation of Nb2-11 cells. XHA06.642 that binds to the rat PRLR blocked the proliferation of Nb2-11 cells. EXAMPLE 7 PROLACTIN-INDUCED STAT5 PHOSPHORILATION INHIBITION IN T47D CELLS BY PROLACTIN RECEPTOR NEUTRALIZING ANTIBODIES
[00430] To analyze the in vitro efficacy of neutralizing PRLR antibodies in an additional reading, inhibition of STAT5 phosphorylation in human T47D cells treated with prolactin was used. T47D cells were grown in RPMI containing 10% FCS and 2 mM glutamine. The cells were seeded in 24-well plates at a density of 0.5 x 105 cells per well. The next day, the cells were deprived for 1 h in RPMI-free serum. Then the cells were incubated with or without different doses of neutralizing antibodies to PRLR or non-specific control antibody in the absence or presence of 20 ng / ml human prolactin for 30 min. Then the cells were rinsed and lysed in 70 μl of lysis buffer. The lysates were centrifuged and the supernatant was frozen at -80 ° C. The extracts were analyzed using western blot (Upstate 07-586 anti-pSTAT5A / B antibody, diluted 1: 1000). As a load control, the blots taken were incubated with anti-beta tubulin antibody (ab7287, diluted 1: 500).
[00431] The results are shown in Figure 7. With the exception of the non-specific FITC antibody, all neutralizing antibodies to PRLR blocked the phosphorylation of STAT5 in human T47D cells in a dose-dependent manner. All antibodies tested bound to human PRLR with high affinity. EXAMPLE 8 INHIBITION OF THE LUCIFERASE REPORTER GENE IN HEK293 CELLS STABLELY TRANSFECTED WITH HUMAN PRLR - ANALYSIS OF PROLACTIN RECEIVER NEUTRALIZING ANTIBODIES AND NON-SPECIFIC CONTROL ANTIBODIES
[00432] To also analyze the in vitro efficacy of neutralizing PRLR antibodies, a reporter gene assay was used. HEK293HEK293 cells stably transfected with human PRLR were transiently transfected with a luciferase reporter gene under the control of LHREs (lactogenic hormone response elements), for 7 hours. Then, the cells were seeded at a density of 20,000 cells per well in a 96-well plate (0.5% serum drawn from coal, DMEM). The next day 300 ng / ml human prolactin with and without increasing doses of neutralizing PRLR antibodies or control antibodies were added. 24 hours later, luciferase activity was determined. The results are described in Figure 8. In contrast to the non-specific antibody, 006-H08 and HE06.642 inhibited luciferase activity in HEK293 cells stably transfected with human PRLR. EXAMPLE 9 INHIBITION OF LUCIFERASE REPORTER GENE IN HEK293 CELLS STABLELY TRANSFECTED WITH MURINO PRLR - ANALYSIS OF PROLACTIN RECEPTOR NEUTRALIZING ANTIBODIES AND NON-SPECIFIC CONTROL ANTIBODIES
[00433] To also analyze the in vitro efficacy of neutralizing PRLR antibodies at the murine prolactin receptor, a reporter gene assay was used. HEK293 cells stably transfected with the murine PRLR were transiently transfected with a luciferase reporter gene under the control of LHREs (lactogenic hormone response elements) for 7 hours. Then, the cells were seeded at a density of 20,000 cells per well in a 96-well plate (0.5% serum drawn from coal, DMEM). On the next day, 200 ng / ml human prolactin with and without increasing doses of neutralizing PRLR antibodies or control antibodies was added. 24 hours later, luciferase activity was determined. The results are described in Figure 9. While the 005-C04 antibody (filled triangles) exhibited high activity (IC50 value = 3 nM), the HE06.642 antibody (filled circles) did not show activity up to 330 nM. The non-specific control antibody (empty circles) is completely inactive. In contrast to the Novartis HE06.642 antibody, the 005-C04 antibody is able to block murine PRLR-mediated signaling. EXAMPLE 10 PROLIFERATION INHIBITION INDUCED BY BAF3 CELL PROLACTIN (STABLE TRANSFECTED WITH THE PROLACTIN MURINO RECEPTOR) BY PROLACTIN RECEIVER NEUTRALIZING ANTIBODIES AND NON-SPECIFIC CONTROL ANTIBODIES
[00434] To analyze the in vitro efficacy of neutralizing PRLR antibodies, inhibition of prolactin-activated cell proliferation of Ba / F3 cells was used. The cells were stably transfected with the murine PRLR and were usually cultured in RPMI containing 2 mM glutamine in the presence of 10% FCS and 10 ng / ml human prolactin. After six hours of deprivation, cells were seeded in 96-well plates at a density of 10,000 cells per well in prolactin-free medium containing 1% FCS. The cells were stimulated with 40 ng / ml prolactin and matched with increasing doses of neutralizing PRLR antibodies for two days. Cell proliferation was analyzed using a CellTiter-Glo Luminescent Cell Viability Assay (Promega). Dose-response curves were generated for the inhibition of prolactin-stimulated cell growth and the calculated IC 50 values. As a negative control, stimulation with a non-specific control antibody was used.
[00435] Dose-response curves and IC50 values are described in Figure 10. The non-specific control antibody (full squares) was inactive for murine PRLR. There was only limited inhibition of murine PRLR activation by antibodies HE06.642, 001-E06, and 001-D07. Only the 005-C04 antibody completely blocked the activation of murine PRLR. EXAMPLE 11 ANTICONCEPTIONAL EFFECT OF NEUTRALIZING ANTIBODIES IGG1 005-C04 FROM PROLACTIN RECEPTOR IN MICE
[00436] To test the influence of neutralizing prolactin receptor antibodies on fertility in mice, female and male NMRI mice at 12 weeks of age were mated for 7 days (day 0 - day 7). Female mice were treated on days -3, 0, 3, and 6 with an intraperitoneal injection of a buffered saline solution with IgG1 phosphate, non-specific control antibody (anti-FITC, 10 mg / kg), or neutralizing antibody IgG1 005-C04 (= IgG1 005-C04) in concentrations of 10 or 30 mg per kg of body weight dissolved in phosphate buffered saline. 10 females were used in each experimental group. Each male was mated with two females, one of the females was from a negative control group or treated with phosphate buffered saline or non-specific antibody, the other female was treated with specific neutralizing antibody. Mating, in which the male did not impregnate the female, were excluded from the data evaluation. Reading parameters were average litter size and pregnancy rates (measured in%) calculated as number of litters per experimental group divided by the number of possible theoretical litters within this group. The results are described in Figure 11.
[00437] Figure 11A shows the pregnancy rates obtained. Pregnancy rates were as follows: - 87.5% in the group of mice treated with phosphate buffered saline, - 75% in the group of mice treated with the non-specific control antibody (10 mg / kg), - 100% in group of mice treated with the neutralizing PRLR antibody IgG1 005-C04 (10 mg / kg), and - 0% in the group of mice treated with the neutralizing PRLR antibody IgG1 005-C04 (30 mg / kg).
[00438] Figure 11B shows the litter sizes observed for the different experimental groups. Litter sizes were as follows: - 10.9 mice per litter in the group of mice treated with phosphate buffered saline, - 12.3 mice per litter in the group of mice treated with the non-specific control antibody (10 mg / kg ), - 13 mice per litter in the group of mice treated with the neutralizing PRLR antibody IgG1 005-C04 (10 mg / kg), and - 0 mice per litter in the group of mice treated with the neutralizing PRLR antibody IgG1 005-C04 (30 mg / kg).
[00439] The results of this mating study demonstrate that the neutralizing prolactin receptor antibody IgG1-005-C04 completely prevented pregnancy in mice when tested at 30 mg / kg body weight. EXAMPLE 12 EPIPT GROUPING
[00440] Epitope pooling experiments were performed using Biacore monitoring the simultaneous binding of pairs of anti-PRLR antibodies to ECD-PRLR (SEQ ID NO: 70). Briefly, the first antibody was covalently immobilized on the sensor slice by coupling the primary amine using n-hydroxysuccinamide (NHC) and N-ethyl-N "-carbodiimide (EDC) dimethylaminopropyl (EDC). Unoccupied binding sites on the surface were then blocked with ethanolamide. Soluble ECD-PRLR (SEQ ID NO: 70) was captured on the surface by means of the immobilized antibody, therefore the epitope of the capture antibody is blocked for all bound ECD-PRLR molecules, a second antibody was passed immediately on the surface to bind to immobilized ECD-PRLR. Two antibodies that recognize the same epitopes or overlapping cannot bind to ECD-PRLR, whereas antibodies with different epitopes can bind. The antibody surface was regenerated with glycine, pH 2.8, to remove the bound proteins and then the process was repeated with other antibodies. All antibody combinations were tested. Representative results are shown on T abela 7. The antibodies 006-H08, 002-H06, 002-H08, 006-H07 and XHA06983 competitively linked to each other in the ECD-PRLR, indicating that they target overlapping epitopes (epitope group 1, table 6). In addition, antibodies competitively bound to PRL which is also the case for 001-E06 (epitope group 2, table 6). This antibody targets a different site than ECD-PRLR than those mentioned above. Finally, the 005-C04 antibody competitively bound to HE06.642 and XHA06.642 without being competitive with PRL (epitope group 3, table 6). TABLE 7: GROUPS OF ANTIBODIES AIMING AT HUMAN PROLACTIN RECEPTOR (PRLR) EXTRACELLULAR DOMAIN (ECD)
EXAMPLE 13 CROSS REACTIVITY OF ANTIBODIES IN HUMAN AND HUMAN PRLR EXPRESSED ON CELL SURFACES
[00441] To determine the binding characteristics of anti-PRLR antibodies in mouse and human PRLR expressed in cells, binding was tested by flow cytometry in HEK293 cells stably expressing human and murine PRLR, respectively. The cells as well as the parental HEK293 cell line without PRLR were harvested, centrifuged and resuspended at about 5x106 cells / ml in 1xPBS containing 2% FBS and 0.1% sodium azide (FACS buffer). Antibodies 005-C04, 001- E06 and HE06.642 were diluted 2 times to final concentration in FACS buffer and added to the appropriate sample wells (50 μl / well). For secondary antibody and autofluorescence controls, 50 μl FACS buffer was added to the appropriate wells. 50 μl of cell suspension was added to each sample well. The samples were incubated at 4 ° C for one hour, washed twice with cold FACS buffer and resuspended in FACS buffer containing goat anti-human IgG conjugated to PE at a dilution of 1: 100. Following a 30 min incubation at 4 ° C, cells were washed twice with cold FACS buffer, resuspended in FACS buffer containing 1 mg / ml of propidium iodide (Invitrogen, San Diego, CA) and analyzed by cytometry. flow. As shown in Figure 13, antibodies 005-C04 and 001- E06 bound to human and murine PRLR in these cells, while HE06.642 only bound to human PRLR. This observation is consistent with the finding reported in example 9 about the lost efficacy of HE06,642 in the murine PRLR-dependent luciferase reporter gene assay. Although 005-C04 and HE06.642 competitively bound to human PRLR, the different binding properties of both antibodies with respect to murine PRLR indicate differences in their epitope specificity. EXAMPLE 14 FAB AND SCFv ANTIBODY INHIBITIVE ACTIVITY IN CELLULAR SIGNALING CASCADES
[00442] To functionally characterize the activity of the Fab and scFv screening repeats in the signaling cascade triggered by PRLR, the inhibition of phosphorylation in the PRLR itself, and in the transcriptional regulators ERK1 / 2 and STAT5 in human T47D cells treated with prolactin, was measures. T47D cells were grown in RPMI containing 2 mM L-glutamine, 10% FBS taken from coal and insulin-transferrin-selenium-A (Gibco). Cells were seeded in 6-well plates or 96-well plates at a density of 1.5 x 106 cells per well. The next day, the growth medium was renewed. On the third day, the cells were deprived for 1 hour in serum-free RPMI. Then the cells were incubated with or without different doses of neutralizing antibodies to PRLR or non-specific control antibody in the presence of 500 ng / ml human prolactin for 5 min. Then the cells were rinsed and lysed in lysis buffer. The lysates were centrifuged and the supernatants were frozen at -80 ° C. The samples were tested by ELISA according to the DuoSet IC "Phospho-prolactin Human R" kit (R&D Systems) for measuring PRLR phosphorylation, according to the PathScan Phospho-STAT5 (Tyr694) sandwich ELISA kit (Cell Signaling Technology; # 7113) for measuring STAT5 phosphorylation and according to the Phospho-ERK1 / ERK2 kit (R&D Systems) for measuring ERK1 / 2 phosphorylation. Table 8 provides an overview of the antagonistic activity of a selection of screening repetitions in Fab or scFv format at a fixed dose of 7.5 μg per ml. TABLE 8: ANTAGONISTIC ACTIVITY OF A SELECTION OF SCREENING REPETITIONS IN PRLR, ERK1 / 2 AND STAT5 PHOSPHORILATION AS DETERMINED BY ELISAS IN HUMAN BREAST CANCER CELL LINER T47D, FAT FORMAT, F FORMAT SC EXAMPLE 15 NEUTRALIZING PRLR ANTIBODIES INHIBIT LACTATION IN MICE

[00443] Adult NMRI females were mated with NMRI males. On postpartum day 1, the litter size was adjusted to 8 mice per lactating mother. The weight of the offspring was determined daily in the morning starting on the postpartum day 1. Lactating mothers remained either untreated (full circles in Figure 14A, B) or were treated intraperitoneally with any non-specific antibody (10 mg / kg body weight; empty circles in Figure 14A, B), or with neutralizing murine PRLR antibody IgG2a 005-C04 containing constant domains (= IgG2a 005-C04; 10 mg / kg, filled triangles in Figure 14A, B) or with neutralizing PRLR IgG2a antibody 005-C04 (30 mg / kg, empty triangles in Figure 14A, B). Group size was 5-6 lactating mothers per experimental group. The mothers were treated with specific or non-specific control antibodies on the postpartum day 1, 3, 6, 9, 10, and 12 (indicated with the arrows in Figure 14A, B). The results are described in Figure 14. Figure 14A shows during each postpartum day the daily litter weight gain expressed as a percentage of the respective litter weight on day 1. From postpartum day 8 onwards, there is a difference weight gain in the litter between the offspring of mothers treated with neutralizing PRLR antibodies and the offspring of mothers who remained untreated or received non-specific control antibodies. Due to ethical reasons, several litters had to be killed on the postpartum day 10 in the experimental group of mothers receiving the highest dose of neutralizing PRLR antibody. In Figure 14B, the results are described differently. The weight gain of the differential litter is described each day and expressed as a percentage of the litter weight on the postpartum day 1. Basically Figure 14B shows the slope of the graphs described in Figure 14A. The daily differential increase in litter weight fluctuates 30% of the litter weight starting around the postpartum day 1 for litters of untreated mothers or mothers treated with non-specific antibody. There is a significant severe reduction in the daily litter weight increase in litters of mothers treated with the neutralizing PRLR antibody at 30 mg / kg body weight from day 7 onwards (* p <0.05; *** p <0.005 vs. litters of mothers treated with non-specific antibody). From postpartum day 11 onwards, the daily weight gain of the litter is significantly decreased also in litters of mothers treated with the neutralizing PRLR antibody at 10 mg / kg compared to litters of mothers treated with non-control antibodies. specific (p <0.05 vs. litters of mothers treated with non-specific antibody). In conclusion, there are dose-dependent effects of the neutralizing PRLR antibody IgG2a 005-C04 on inhibition of lactation. Figure 14C shows the histological sections of the mammary glands of lactating mothers from different experimental groups. The mammary glands of untreated mothers and mothers treated with non-specific control antibodies are filled with milk-producing ducts. In contrast, there are signs of involution of the mammary gland in mothers treated with the neutralizing PRLR antibody IgG2a 005-C04. Black arrows in Figure 14C point to islands of fat in the mammary gland tissue (see dose-dependent effect of specific antibody IgG2a 005-C04 on the extent of mammary gland involution (Figure 14C)). In addition, the expression of beta-casein from the main milk proteins (Csn-2), whey acidic protein (WAP), and IGF-1 was analyzed in the mammary glands of mothers from different experimental groups (Figure 14D). Gene expression was normalized to the expression of TATA box binding protein (TBP). The neutralizing PRLR antibody IgG2a 005-C04 in a dose-dependent manner decreased the expression of milk protein whereas the non-specific antibody (10 mg / kg) was without any significant effect.
[00444] The neutralizing PRLR antibody IgG2a 005-C04 in a dose-dependent manner blocked lactation and led to the involution of the mammary gland in lactating mice, which demonstrated its usefulness for inhibiting lactation. EXAMPLE 16 NEUTRALIZING PRLR ANTIBODIES ARE SUITABLE FOR THE TREATMENT OF BENIGAN BREAST DISEASE
[00445] A PRLR activating mutation or local or systemic hyperprolactinemia can cause benign breast disease. Therefore, a hyperprolactinemic mouse model to induce intensified proliferation in the mammary gland (conspicuous of the most severe forms of benign breast disease) was employed. On day 0, 12-week-old female Balb / c mice received a pituitary isograft under the renal capsule or remained without surgery. Pituitary iso-grafted mice remained untreated or were treated intraperitoneally with non-specific antibody (10 mg / kg), neutralizing antibody to PRLR 005-C04 in IgG1 format (= IgG1 005-C04; 10 mg / kg), or neutralizing antibody to PRLR IgG1 005-C04 (30 mg / kg) on days 0, 3, 7, 11, and 15. Size of the experimental group was 8-10 animals. On the 17th day after, the pituitary transplant mice were sacrificed. Two hours before death, the animals received an intraperitoneal injection of BrdU to monitor the proliferation of epithelial cells. The left mammary gland was fixed in Carnoy's solution and whole mounds of the mammary gland were prepared and stained with Carmine alaune (Figure 15A). The right inguinal mammary gland was fixed in 4% phosphate-buffered formalin during the night. Mammary glands were subsequently embedded in paraffin and BrdU immunostaining was performed as previously described (Endocrinology 149 (8): 3952-3959; 2009). In addition, pSTAT5 immunostaining was performed (anti abcam pSTAT5 antibody, ab32364, diluted 1:60) to monitor inhibition of PRLR-mediated signaling in response to treatment with neutralizing PRLR antibodies. Figure 15A shows enlargements of the entire mammary gland mounds from different experimental groups. Mammary glands of adult mice that did not receive a pituitary show terminal ducts and shoots, while there is extreme bifurcation and formation of alveolar structures in mice that receive a pituitary isograft. Treatment with non-specific antibody (10 mg / kg) does not inhibit bifurcation and formation of alveolar structures. In contrast, treatment with neutralizing antibody IgG1 005-C04 at 10 mg / kg body weight leads to complete inhibition of bifurcation in 8 out of 10 animals receiving a pituitary isograft and treatment with IgG1 005-C04 at 30 mg / kg completely inhibits bifurcation in 9 out of 9 animals that receive a pituitary isograft. Histological analysis and immunostaining of BrdU are described in Figure 15B. Pituitary isograft leads to epithelial hyperplasia that is not inhibited by treatment with non-specific antibody, whereas there is no epithelial hyperplasia in mice harboring a pituitary isograft and treated with the neutralizing PRLR antibody at a dose of 10 or 30 mg / kg weight of the body. Some of the BrdU-positive cells, reflecting the cells in the S phase of the cell cycle that are going to divide, are indicated by white arrows in Figure 15B. Mice treated with the neutralizing antibody IgG1 005-C04 (30 mg / kg body weight) showed almost complete inhibition of epithelial cell proliferation in mammary glands. Some of the phospho-STAT5 positive cells are indicated by white arrows in Figure 15C. Treatment with 30 mg / kg IgG1 005-C04 leads to complete inhibition of STAT5 phosphorylation, indicating complete blocking of PRLR-mediated signaling.
[00446] The results of Figure 15A, B, and C demonstrated that neutralizing antibodies to PRLR are suitable for the treatment of mastopathy, a benign proliferative disease of the mammary gland. Neutralizing PRLR antibodies inhibit the proliferation of breast epithelial cells and the activation of phospho-STAT5. EXAMPLE 17 TREATMENT OF BENIGAN PROSTATE HYPERPLASIA WITH PRLR NEUTRALIZING ANTIBODIES
[00447] Benign prostatic hyperplasia has been established in male Balb / c mice by grafting two pituitary under the renal capsule at the age of 8 weeks. A control group remained without operating. Mice receiving pituitary isografts remained untreated or received intraperitoneal injections of either a non-specific antibody (10 mg / kg), or the neutralizing PRLR antibody 005-C04 IgG2a murine containing constant domains (= IgG2a 005-C04) at doses of 10 and 30 mg / kg body weight. Antibody injections were performed starting on the day of pituitary transplantation (= day 0), and on day 3, day 7, day 11, day 15, day 18, day 22, and day 25 after pituitary transplantation. The mice were sacrificed on day 28. The relative weight of the ventral prostate was determined. The results are described in Figure 16. Pituitary isograft resulted in an increase in the relative weight of the prostate. Treatment with 10 mg / kg and 30 mg / kg of neutralizing PRLR IgG2a 005-C04 antibody reduced the weight of the prostate while treatment with non-specific control antibody was without any effect. Neutralizing PRLR antibodies are therefore suitable for the treatment of benign prostatic hyperplasia.
[00448] On day 18 after pituitary isograft it was evident that hair growth was slowed in animals receiving pituitary isografts. Neutralizing PRLR antibodies stimulated hair growth under hyperprolactinemic conditions. Representative photographs are shown in Figure 17. PRLR neutralizing antibodies can therefore be used for the treatment of hyperprolactinemic hair loss. EXAMPLE 18 EFFECT OF PRLR NEUTRALIZING ANTIBODIES ON HAIR GROWTH
[00449] The dorsal hair of 8-week-old male and female C57BL / 6 mice was removed using electric scrapers as previously described (British Journal of Dermatology 2008; 159: 300-305). Hyperprolactinemia was induced in some groups through a pituitary isograft under the renal capsule, the animals in the remaining groups were normoprolactinemic. The animals were treated with specific PRLR antibodies (IgG2a 005-C04) or non-specific control antibodies (30 mg / kg, intraperitoneally) once weekly (starting on day 0, which is the day of the pituitary isograft). Subsequent antibody injections were performed on days 7 and 14. After three weeks, hair regrowth was visible as dark parts of the shaved pink-white skin, and the percentage of the shaved area that became dark was measured. The female mice were killed 15 days after scraping and the male mice were sacrificed 18 days after scraping.
[00450] The following experimental groups were used (group size was 6 mice): 1. shaved females 2. shaved females with pituitary isograft 3. females shaved with pituitary isograft + 30 mg / kg of non-specific IgG2a 005-C04 an once weekly 4. females shaved with pituitary isograft + 30 mg / kg of specific antibody once weekly 5. shaved females + 30 mg / kg of non-specific antibody once weekly 6. females shaved + 30 mg / kg of specific antibody once weekly 7. shaved males 8. shaved males with pituitary isograft 9. shaved males with pituitary isograft + 30 mg / kg of non-specific antibody once weekly 10. shaved males with pituitary isograft + 30 mg / kg specific antibody IgG2a 005-C04 one once weekly 11. shaved males + 30 mg / kg of non-specific antibody once weekly 12. shaved males + 30 mg / kg of specific antibody once weekly
[00451] Representative figures of the animals of the different groups are represented in Figure 18, the percentage of the regrowth of the fur area is indicated in Figure 18.
[00452] PRLR neutralizing antibodies, but not nonspecific antibodies, stimulate hair regrowth under hyper and normoprolactinemic conditions in male and female mice. Neutralizing PRLR antibodies are therefore suitable for treating hair loss in women and men under hyper and normoprolactinemic conditions. EXAMPLE 19 INHIBITION OF INTENSIFIED PROLIFERATION OF BREAST EPITHELIAL CELLS BY PRLR NEUTRALIZING ANTIBODIES
[00453] To test the effect of neutralizing PRLR antibodies on proliferation of intensified breast epithelial cells activated by combined hormonal therapy (ie, estrogen plus progestin therapy) a previously described mouse model that allowed the quantification of proliferative effects in the uterus and in the mammary gland it was used (Endocrinology 149: 3952-3959,2008). 6-week-old female C57BL / 6 mice were ovariectomized. 2 weeks after ovariectomy, the animals were treated subcutaneously with daily injections of either vehicle (ethanol / arachisoil 10% / 90%) or 100 ng estradiol plus 100 mg / kg progesterone for two weeks. Animals were treated once weekly with intraperitoneal injections of neutralizing PRLR antibodies (10 mg / kg and 30 mg / kg) in the form of murine IgG2a or non-specific antibody (30 mg / kg) for three weeks. Autopsy was performed on day 36 after ovariectomy. Two hours before death, the animals received an intraperitoneal injection of bromodeoxyuridine (BrdU) dissolved in phosphate buffered saline (70 mg / kg body weight). The proximal 2/3 of the right inguinal mammary gland were analyzed for the proliferation of mammary epithelial cells (immunostaining of BrdU) previously described (Endocrinology 149: 3952-3959,2008).
[00454] The experiment comprised the following groups: 1. ovariectomized animals treated with vehicle 2. ovariectomized animals treated with 100 ng estradiol 3. ovariectomized animals treated with 100 ng estradiol (E) and 100 mg / kg progesterone (P) 4. animals ovariectomized animals treated with E + P and 10 mg / kg of specific antibody 005-C04 5. ovariectomized animals treated with E + P and 30 mg / kg of specific antibody 005-C04 6. ovariectomized animals treated with E2 + P and 30 mg / kg of non-specific control antibody
[00455] The results are shown in Figure 19. The absolute number of proliferative ductal epithelial cells within 4 cross sections of the mammary gland was evaluated. The averages are described as horizontal bars. Proliferation of epithelial cells in vehicle-treated ovariectomized mice is quite low. Estradiol treatment leads to some stimulation of epithelial cell proliferation, maximum mammary epithelial cell proliferation is seen under estrogen plus progesterone treatment (Figure 19). Treatment with 005-C04 neutralizing antibody prolactin receptor but not with non-specific control antibody leads to a dose-dependent decrease in mammary epithelial cell proliferation almost again to estradiol levels only.
[00456] PRLR neutralizing antibodies are therefore suitable for treating enhanced proliferation of mammary epithelial cells under combined hormonal therapy, i.e. treatment of estradiol plus progesterone. EXAMPLE 20 TREATMENT OF ADENOMYOSIS UTERS (= INTERNAL ENDOMETRIOSIS) IN SHN MICE WITH PRLR NEUTRALIZING ANTIBODIES
[00457] To test the effectiveness of PRLR neutralizing antibodies in endometriosis, the adenomyosis uterus model in SHN mice that have systemic hyperprolactinemia was used (Acta anat. 116: 46-54,1983). Hyperprolactinemia in SHN mice was induced by a pituitary isograft under the renal capsule of 7-week-old female mice (Acta anat. 116: 46-54,1983). Neutralizing PRLR antibodies (10 mg / kg or 30 mg / kg) or non-specific antibodies (30 mg / kg) were administered intraperitoneally starting one week after pituitary isograft. The infiltration of the uterine muscle layer through glandular tissue was evaluated as previously described (Laboratory Animal Science 1998,48: 64-68). Antibody treatment was performed for 9 weeks once and twice weekly via intraperitoneal injections. At autopsy (day 70 after pituitary transplantation), the uteri were fixed overnight in 4% buffered formalin and embedded in paraffin. The degree of adenomyosis (= internal endometriosis) was assessed as follows: Grade 0 = no adenomyosis Grade 0.5 = the inner layer of the myometrium loses its concentric orientation Grade 1 = endometrial glands invading the inner layer of the myometrium Grade 2 = endometrial glands between the inner and outer layer of the uterine myometrium Grade 3 = endometrial glands invading the outer layer of the uterine myometrium Grade 4 = endometrial glands outside the outer layer of the uterine myometrium
[00458] The experiment comprised the following experimental groups: 1. Animals without pituitary transplantation, that is, normoprolactinemic mice 2. Animals with pituitary transplantation, that is, hyperprolactinemic mice 3. Animals with pituitary transplantation, treated with control antibody non-specific once weekly at a dose of 30 mg / kg 4. Animals with pituitary transplantation, treated with nonspecific control antibody twice weekly at a dose of 30 mg / kg 5. Animals with pituitary transplantation, treated with neutralizing antibody to the 005-C04 prolactin receptor in the murine IgG2a format once weekly at a dose of 10 mg / kg 6. Animals with pituitary transplantation, treated with the neutralizing antibody of the 005-C04 prolactin receptor in the murine IgG2a format twice weekly at a dose of 10 mg / kg 7. Animals with pituitary transplantation, treated with the neutralizing antibody of the d receptor prolactin 005-C04 in murine IgG2a format once weekly at a dose of 30 mg / kg 8. Animals with pituitary transplantation, treated with the neutralizing antibody to the 005-C04 prolactin receptor in murine IgG2a format twice weekly at a dose of 30 mg / kg
[00459] The results are described in Figure 20. The counts for each animal in each treatment group are individually given and the averages shown for each treatment group as horizontal bars. Normoprolactinemic mice develop internal endometriosis to some extent (mean disease count = 0.25). Hyperprolactinemia due to the pituitary isograft intensifies the disease count and more animals suffer from the disease (mean disease count = 2.5). While treatment with 30 mg / kg of non-specific antibody once or twice a week had no influence on the disease, treatment with specific neutralizing antibodies shows a dose-dependent decrease in disease count. Notably, all animals receiving 10 or 30 mg / kg of specific antibody twice a week were completely cured and their disease count was significantly lower than the disease count of normoprolactinemic mice (Figure 20). Neutralizing PRLR antibodies are therefore suitable for treating internal endometriosis (= adenomyosis uteri) and external endometriosis in women. EXAMPLE 21 MATURATION OF ANTIBODY VARIABLES:
[00460] Antibody affinity maturation is a two-step process where saturation mutagenesis and high throughput screening are combined to identify a small number of mutations that result in increases in affinity. In the first affinity maturation cycle, positional diversification of the wild-type antibody is introduced through directed mutagenesis using NNK-trinucleotide cassettes (whereby N represents a 25% mixture of each of the adenine, thymine, guanine nucleotides , and cytosine and K represents a 50% mixture of each of the nucleotides of thymine and guanine) according to BMC Biotechnology 7: 65, 2007. In this way, all 20 amino acids are introduced into an individual amino acid position. This positional randomization is restricted to the six complementarity determining regions (CDRs). In the second affinity maturation cycle, beneficial substitutions were recombined and screened for further improvement. SCREENING OF MATURE VARIANTES FROM 006-H08 BY HOMOGENEOUS FLUORESCENCE TEST RESOLVED IN TIME (HTRF):
[00461] Supernatants derived from normalized E. coli and 8 nM of biotinylated extracellular domain of PRLR together with 1 nM of Streptavidin-Europium were incubated in 96-well microtiter plates for 30 min. Then 200 mM KF and 50 nM Alexa Fluorine 647 IgG1 from 006-H08 were added. This mixture was incubated at room temperature for 5, 20, 35, 50, and 65 minutes, respectively. At the indicated time points, absorption at 665 nm (and 620 nm) was measured using EnVision MultilabelReader (Perkin Elmer). The results obtained are shown in Figure 21.
权利要求:
Claims (17)
[0001]
1. Antibody 006-H08 that antagonizes signaling mediated by the prolactin receptor and that binds epitopes of the extracellular domain of the prolactin receptor and human polymorphic variants thereof, characterized by the fact that the amino acid sequence of the extracellular domain of the prolactin receptor prolactin corresponds to SEQ ID NO: 70, and the nucleic acid sequence corresponds to SEQ ID NO: 71, where SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO : 13 corresponds to HCDR3 and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3, and where a. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 78 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 90 corresponds to LCDR3; or b. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 75 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 82 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 91 corresponds to LCDR3; or c. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 82 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3; or d. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 86 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3; or e. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 87 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 100 corresponds to LCDR3; or f. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 87 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 92 corresponds to LCDR3; or g. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 89 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 93 corresponds to LCDR3; or h. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 79 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 101 corresponds to LCDR3, or i. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 76 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 89 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 90 corresponds to LCDR3; or j. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 100 corresponds to LCDR3; or k. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 97 corresponds to LCDR3; or l. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 98 corresponds to LCDR3; or m. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 83 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 99 corresponds to LCDR3; or no. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 96 corresponds to LCDR3; or the. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 94 corresponds to LCDR3; or p. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 88 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 90 corresponds to LCDR3; or q. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 74 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 81 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 95 corresponds to LCDR3; or r. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 75 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3; or s. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 77 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3; or t. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 80 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3; or u. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 85 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3 9; or V. SEQ ID NO: 1 of the heavy variable chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 84 of the light variable chain corresponds to LCDR1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3.
[0002]
2. Antibody according to claim 1, characterized by the fact that: a. 006-H08 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 46, and an amino acid sequence according to SEQ ID NO: 34, and a light variable domain with a nucleic acid sequence according to SEQ ID NO: 52, and an amino acid sequence according to SEQ ID NO: 40, b. 006-H08-12-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 331, and an amino acid sequence according to SEQ ID NO: 353, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 165, and an amino acid sequence according to SEQ ID NO: 143, c. 006-H08-13-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 332, and an amino acid sequence according to SEQ ID NO: 354, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 166, and an amino acid sequence according to SEQ ID NO: 144, d. 006-H08-13-6-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 333, and an amino acid sequence according to SEQ ID NO: 355, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 167, and an amino acid sequence according to SEQ ID NO: 145, e.g. 006-H08-14-6-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 334, and an amino acid sequence according to SEQ ID NO: 356, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 168, and an amino acid sequence according to SEQ ID NO: 146, f. 006-H08-15-5 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 335, and an amino acid sequence according to SEQ ID NO: 357, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 169, and an amino acid sequence according to SEQ ID NO: 147, g. 006-H08-19-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 336, and an amino acid sequence according to SEQ ID NO: 358, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 170, and an amino acid sequence according to SEQ ID NO: 148, h. 006-H08-29-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 337, and an amino acid sequence according to SEQ ID NO: 359, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 171, and an amino acid sequence according to SEQ ID NO: 149, i. 006-H08-32-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 338, and an amino acid sequence according to SEQ ID NO: 360, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 172, and an amino acid sequence according to SEQ ID NO: 150, j. 006-H08-33-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 339, and an amino acid sequence according to SEQ ID NO: 361, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 173, and an amino acid sequence according to SEQ ID NO: 151, k. 006-H08-33-16-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 340, and an amino acid sequence according to SEQ ID NO: 362, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 174, and an amino acid sequence according to SEQ ID NO: 152, l. 006-H08-35-17-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 341, and an amino acid sequence according to SEQ ID NO: 363, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 175, and an amino acid sequence according to SEQ ID NO: 153, m. 006-H08-35-17-4 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 342, and an amino acid sequence according to SEQ ID NO: 364, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 176, and an amino acid sequence according to SEQ ID NO: 154, n. 006-H08-35-1 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 343, and an amino acid sequence according to SEQ ID NO: 365, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 177, and an amino acid sequence according to SEQ ID NO: 155, o. 006-H08-36-17-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 344, and an amino acid sequence according to SEQ ID NO: 366, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 178, and an amino acid sequence according to SEQ ID NO: 156, p. 006-H08-37-19-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 345, and an amino acid sequence according to SEQ ID NO: 367, and a light variable chain domain with a nucleic acid sequence according to SEQ ID NO: 179, and an amino acid sequence according to SEQ ID NO: 157, q. 006-H08-39-7 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 346, and an amino acid sequence according to SEQ ID NO: 368, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 180, and an amino acid sequence according to SEQ ID NO: 158, r. 006-H08-48-5 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 347, and an amino acid sequence according to SEQ ID NO: 369, and a domain of the light variable chain with a nucleic acid sequence according to SEQ ID NO: 181, and an amino acid sequence according to SEQ ID NO: 159, s. 006-H08-53-27-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 348, and an amino acid sequence according to SEQ ID NO: 370, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 182, and an amino acid sequence according to SEQ ID NO: 160, t. 006-H08-59-30-0 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 349, and an amino acid sequence according to SEQ ID NO: 371, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 183, and an amino acid sequence according to SEQ ID NO: 161, u. 006-H08-63-32-4 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 350, and an amino acid sequence according to SEQ ID NO: 372, and a light variable chain domain with a nucleic acid sequence according to SEQ ID NO: 184, and an amino acid sequence according to SEQ ID NO: 162, v. 006-H08-65-33-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 351, and an amino acid sequence according to SEQ ID NO: 373, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 185, and an amino acid sequence according to SEQ ID NO: 163, w. 006-H08-68-35-2 comprises a heavy variable chain domain that corresponds to a nucleic acid sequence according to SEQ ID NO: 352, and an amino acid sequence according to SEQ ID NO: 374, and a light chain domain with a nucleic acid sequence according to SEQ ID NO: 186, and an amino acid sequence according to SEQ ID NO: 164.
[0003]
Antibody according to claim 1 or 2, characterized in that it consists of an antigen binding region that specifically binds or has a high affinity for one or more PRLR regions, the amino acid sequence of which is described by SEQ ID NO: 70 and human polymorphic variants of SEQ ID NO: 70, amino acid position 1 to 210, whereby affinity is at least 100 nM, preferably less than about 100 nM, more preferably less than about 30 nM, even more preferred with an affinity of less than about 10 nM, or even more preferred with an affinity of less than 1 nM.
[0004]
Antibody according to any one of claims 1 to 3, characterized in that the heavy constant is a modified or unmodified IgG1, IgG2, IgG3 or IgG4.
[0005]
An isolated nucleic acid sequence, characterized by the fact that it encodes an antibody or antigen binding fragment as defined in any one of claims 1 to 4.
[0006]
6. Expression vector, characterized by the fact that it comprises a nucleic acid sequence as defined in claim 5.
[0007]
7. Transgenic microorganism, characterized by the fact that it comprises the vector as defined in claim 6 or a nucleic acid molecule as defined in claim 5, wherein the transgenic microorganism is a yeast cell or a bacterial cell.
[0008]
8. Method of using the transgenic microorganism as defined in claim 7, to produce an antibody or antigen binding fragment, characterized by the fact that it comprises the step of cultivating the transgenic microorganism under suitable conditions and recovering said antibody.
[0009]
Antibody or antigen binding fragment according to any one of claims 1 to 4, characterized in that it is purified to at least 95% homogeneity by weight.
[0010]
10. Pharmaceutical composition, characterized in that it comprises the antibody or antigen binding fragment as defined in any one of claims 1 to 4, and a pharmaceutically acceptable carrier comprising excipients and auxiliaries.
[0011]
11. Kit, characterized by the fact that it comprises an antibody as defined in any one of claims 1 to 4, comprising a therapeutically effective amount of antibody 006-H08 or matured variants thereof, packaged in a container, in which optionally still contains a second therapeutic agent.
[0012]
12. Antibody or antigen binding fragment according to claims 1 to 4, characterized by the fact that it is for use as a medicine for the treatment and / or prevention of endometriosis and adenomyosis (internal endometriosis).
[0013]
13. Antibody or antigen binding fragment according to claims 1 to 4, characterized in that it is for use as a medicine for the treatment of benign breast disease and mastalgia.
[0014]
14. Antibody or antigen binding fragment according to claims 1 to 4, characterized in that it is for use as a medicine for inhibiting lactation.
[0015]
15. Antigen or antigen binding fragment according to claims 1 to 4, characterized in that it is for use as a medicine for the treatment of benign prostatic hyperplasia.
[0016]
16. Antibody or antigen binding fragment according to claims 1 to 4, characterized in that it is for use as a medicine for the treatment of hyper and normoprolactinemic hair loss.
[0017]
Pharmaceutical composition according to claim 11, characterized in that it comprises PRLR antibodies or antigen binding fragment as defined in any one of claims 1 to 4, in combination with at least one other agent.
类似技术:
公开号 | 公开日 | 专利标题
BR112012015852B1|2020-12-29|prolactin receptor antibody, isolated nucleic acid sequence, expression vector, transgenic microorganism, method of production, pharmaceutical composition and kit
BR112012014048B1|2021-10-26|PROLACTIN RECEPTOR ANTIBODIES OR ANTIGEN BINDING FRAGMENTS, THEIR USES, NUCLEIC ACID SEQUENCE, EXPRESSION VECTOR AS WELL AS HOST CELL AND ITS USE
BR112013030995B1|2021-11-09|MAT3 ANTIBODY OR ANTIGEN-BINDING FRAGMENTS OF THE SAME, ITS USES, ISOLATED NUCLEIC ACID SEQUENCE, EXPRESSION VECTOR, HOST CELL AND ITS METHOD OF USE, PHARMACEUTICAL COMPOSITION, AND KITS
同族专利:
公开号 | 公开日
TW201130505A|2011-09-16|
EP2567978A1|2013-03-13|
NZ600511A|2014-01-31|
EP2510006A1|2012-10-17|
EP2567977A1|2013-03-13|
US20120315276A1|2012-12-13|
TW201138817A|2011-11-16|
CU23973B1|2013-12-27|
CN102947338A|2013-02-27|
HUE031631T2|2017-07-28|
AU2010330161B2|2015-07-09|
DOP2012000159A|2012-09-30|
TW201130506A|2011-09-16|
JP6066474B2|2017-01-25|
CR20120310A|2012-08-01|
TWI508744B|2015-11-21|
BR112012014048A2|2017-10-31|
MX339343B|2016-05-20|
CN102741291A|2012-10-17|
CY1118407T1|2017-06-28|
JP6199930B2|2017-09-20|
JP2013513365A|2013-04-22|
CA2783513C|2018-08-14|
JP2015180690A|2015-10-15|
AR079641A1|2012-02-08|
US20130129739A1|2013-05-23|
HK1180354A1|2013-10-18|
WO2011069796A1|2011-06-16|
CA2783610C|2018-10-30|
AU2010330161A1|2012-07-05|
EP2510005A1|2012-10-17|
IN2012DN05078A|2015-10-23|
AR079351A1|2012-01-18|
CA2783514A1|2011-06-16|
HK1180700A1|2013-10-25|
JP2013513361A|2013-04-22|
TW201130507A|2011-09-16|
CR20120312A|2012-08-27|
US20120321632A1|2012-12-20|
WO2011069798A1|2011-06-16|
EP2510006B1|2016-11-09|
ES2610654T3|2017-04-28|
JP2013513364A|2013-04-22|
EP2510002B1|2016-08-24|
TW201130504A|2011-09-16|
KR101765968B1|2017-08-08|
IN2012DN05082A|2015-10-09|
US9649374B2|2017-05-16|
US20130022606A1|2013-01-24|
HUE030143T2|2017-04-28|
WO2011069794A1|2011-06-16|
US9241989B2|2016-01-26|
EA029327B1|2018-03-30|
EP2510003A1|2012-10-17|
CU20120092A7|2012-10-15|
CA2783513A1|2011-06-16|
CA2783651A1|2011-06-16|
NZ600512A|2014-11-28|
TWI487536B|2015-06-11|
CU20120093A7|2012-10-15|
PL2510006T3|2017-06-30|
AU2010330165A1|2012-07-19|
US20130272968A1|2013-10-17|
CN102947338B|2015-11-25|
WO2011069795A4|2011-08-18|
SG181511A1|2012-07-30|
HRP20170016T1|2017-02-24|
CN102858804A|2013-01-02|
CN102884082A|2013-01-16|
CA2783610A1|2011-06-16|
CA2783654A1|2011-06-16|
MA33888B1|2013-01-02|
RS55589B1|2017-06-30|
CL2012001540A1|2013-01-18|
GT201200186A|2014-01-06|
JP2013513559A|2013-04-22|
ECSP12011965A|2012-07-31|
EA201200851A1|2013-01-30|
DK2510002T3|2016-11-28|
AU2010330165B2|2015-07-16|
AR079349A1|2012-01-18|
HRP20161401T1|2016-12-16|
AR079352A1|2012-01-18|
SI2510002T1|2016-12-30|
JP2013513363A|2013-04-22|
BR112012015852A8|2017-06-27|
WO2011069797A1|2011-06-16|
WO2011069795A1|2011-06-16|
EP2332995A1|2011-06-15|
SI2510006T1|2017-02-28|
LT2510002T|2016-11-25|
ME02577B|2017-06-20|
CA2783678A1|2011-06-16|
RS55277B1|2017-02-28|
EP2567979A1|2013-03-13|
AP2012006343A0|2012-06-30|
CN102858801A|2013-01-02|
KR20120112527A|2012-10-11|
PE20121561A1|2012-11-25|
AR079348A1|2012-01-18|
PT2510006T|2017-01-20|
PE20121360A1|2012-10-11|
CN102858803A|2013-01-02|
IL220149D0|2012-07-31|
MX2012006621A|2012-10-05|
IL220149A|2017-09-28|
PT2510002T|2016-11-23|
KR20120112528A|2012-10-11|
PL2510002T3|2017-02-28|
CY1118209T1|2017-06-28|
ZA201204213B|2014-08-27|
EP2570435A1|2013-03-20|
SG181513A1|2012-07-30|
KR101790366B1|2017-10-26|
EP2510002A1|2012-10-17|
EA201200860A1|2013-01-30|
PE20171134A1|2017-08-09|
LT2510006T|2016-12-12|
JP2013513362A|2013-04-22|
CN102884082B|2015-05-20|
MX2012006620A|2012-06-21|
WO2011069799A1|2011-06-16|
AR079350A1|2012-01-18|
CL2012001539A1|2012-10-12|
EP2570436A1|2013-03-20|
EP2567980A1|2013-03-13|
IL220151D0|2012-07-31|
ZA201204214B|2014-08-27|
EP2510004A1|2012-10-17|
DOP2012000160A|2012-09-30|
BR112012015852A2|2017-05-23|
US20130171147A1|2013-07-04|
TN2012000294A1|2013-12-12|
EP2510007A1|2012-10-17|
ECSP12011966A|2012-07-31|
BR112012015852B8|2021-05-25|
EA028678B1|2017-12-29|
ES2603352T3|2017-02-27|
DK2510006T3|2017-01-23|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US4657760A|1979-03-20|1987-04-14|Ortho Pharmaceutical Corporation|Methods and compositions using monoclonal antibody to human T cells|
US4634665A|1980-02-25|1987-01-06|The Trustees Of Columbia University In The City Of New York|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|
US4399216A|1980-02-25|1983-08-16|The Trustees Of Columbia University|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|
US5179017A|1980-02-25|1993-01-12|The Trustees Of Columbia University In The City Of New York|Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials|
US4510245A|1982-11-18|1985-04-09|Chiron Corporation|Adenovirus promoter system|
US4816567A|1983-04-08|1989-03-28|Genentech, Inc.|Recombinant immunoglobin preparations|
US5168062A|1985-01-30|1992-12-01|University Of Iowa Research Foundation|Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence|
US5206344A|1985-06-26|1993-04-27|Cetus Oncology Corporation|Interleukin-2 muteins and polymer conjugation thereof|
US4968615A|1985-12-18|1990-11-06|Ciba-Geigy Corporation|Deoxyribonucleic acid segment from a virus|
US4986615A|1988-10-17|1991-01-22|The Vendo Company|Vending apparatus|
US5530101A|1988-12-28|1996-06-25|Protein Design Labs, Inc.|Humanized immunoglobulins|
US5225212A|1989-10-20|1993-07-06|Liposome Technology, Inc.|Microreservoir liposome composition and method|
GB9105245D0|1991-03-12|1991-04-24|Lynxvale Ltd|Binding molecules|
US5766886A|1991-12-13|1998-06-16|Xoma Corporation|Modified antibody variable domains|
DK1143006T3|1995-08-18|2008-07-14|Morphosys Ip Gmbh|Vectors / DNA sequences from human combinatorial antibody libraries|
JP2001500865A|1996-09-13|2001-01-23|ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ|Non-hormonal method of contraception|
GB9701425D0|1997-01-24|1997-03-12|Bioinvent Int Ab|A method for in vitro molecular evolution of protein function|
US6867187B2|2000-12-22|2005-03-15|Trustees Of The University Of Pennsylvania|Composition and method for modulating somatolactogenic function|
EP1325930A1|2002-01-08|2003-07-09|Institut National De La Sante Et De La Recherche Medicale |Mammal prolactin variants|
US6995244B2|2002-12-13|2006-02-07|The Ohio State University|Antagonists for human prolactin|
GB0305790D0|2003-03-13|2003-04-16|Glaxosmithkline Biolog Sa|Novel Composition|
WO2006046689A1|2004-10-28|2006-05-04|Kyowa Hakko Kogyo Co., Ltd.|Remedy for endometriosis|
WO2006089678A2|2005-02-22|2006-08-31|Bioinvent International Ab|Antibodies and peptides binding to hiv tat, and uses thereof|
GB0517878D0|2005-09-02|2005-10-12|Bioinvent Int Ab|Immunotherapeutic treatment|
US7422899B2|2005-10-05|2008-09-09|Biogen Idec Ma Inc.|Antibodies to the human prolactin receptor|
TWI454480B|2006-08-18|2014-10-01|Novartis Ag|Prlr-specific antibody and uses thereof|
EP2167101A2|2007-05-30|2010-03-31|Auckland Uniservices Limited|Antibodies and sirna against growth hormone, prolactin and proliferin for use in the treatment of tumors and endometriosis|
EP2025683A1|2007-08-13|2009-02-18|INSERM |Variants of prolactin as antagonists of its receptor|
EP2332995A1|2009-12-10|2011-06-15|Bayer Schering Pharma Aktiengesellschaft|Neutralizing prolactin receptor antibodies and their therapeutic use|
WO2011139375A1|2010-05-06|2011-11-10|Ludwig Institute For Cancer Research Ltd|Antibodies directed against carbonic anhydrase ix and methods and uses thereof|
GB201020995D0|2010-12-10|2011-01-26|Bioinvent Int Ab|Biological materials and uses thereof|EP2332995A1|2009-12-10|2011-06-15|Bayer Schering Pharma Aktiengesellschaft|Neutralizing prolactin receptor antibodies and their therapeutic use|
CA3101298A1|2010-03-01|2011-09-09|Bayer Healthcare Llc|Optimized monoclonal antibodies against tissue factor pathway inhibitor |
EP2530089A1|2011-06-03|2012-12-05|Bayer Pharma Aktiengesellschaft|Neutralising prolactin receptor antibody Mat3 and its therapeutical use|
US8883979B2|2012-08-31|2014-11-11|Bayer Healthcare Llc|Anti-prolactin receptor antibody formulations|
US9592297B2|2012-08-31|2017-03-14|Bayer Healthcare Llc|Antibody and protein formulations|
PT2935331T|2012-12-24|2018-06-04|Abbvie Inc|Prolactin receptor binding proteins and uses thereof|
UY35460A|2013-03-15|2014-10-31|Bayer Healthcare Llc|FORMULATIONS OF ANTIBODIES ANTI-RECEIVER OF PROLACTIN|
TWI641620B|2013-08-21|2018-11-21|再生元醫藥公司|Anti-prlr antibodies and uses thereof|
US9545451B2|2013-08-21|2017-01-17|Regeneron Pharmaceuticals, Inc.|Anti-PRLR antibodies and methods for killing PRLR-expressing cells|
US10308697B2|2014-04-30|2019-06-04|President And Fellows Of Harvard College|Fusion proteins for treating cancer and related methods|
AU2015327824B2|2014-10-02|2021-01-07|City Of Hope|Multivalent meditopes, meditope-binding antibodies and uses thereof|
WO2016121908A1|2015-01-30|2016-08-04|学校法人埼玉医科大学|Anti-alk2 antibody|
CN107849131A|2015-07-06|2018-03-27|瑞泽恩制药公司|Polyspecific antigen binding molecules and application thereof|
AU2017366873A1|2016-11-29|2019-06-13|Regeneron Pharmaceuticals, Inc.|Methods of treating PRLR positive breast cancer|
FR3062213B1|2017-01-20|2021-02-26|Endodiag|USE OF THE CD71 RECEIVER IN THE DETECTION AND TREATMENT OF ENDOMETRIOSIS|
TW201836647A|2017-04-06|2018-10-16|美商艾伯維有限公司|Anti-prlr antibody-drug conjugatesand uses thereof|
JP2020519639A|2017-05-12|2020-07-02|ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc.|Treatment of gastroparesis with triazaspiro[4.5]decanone|
AU2018300687A1|2017-07-10|2019-12-19|Bayer Pharma Aktiengesellschaft|Prolactin receptor antibody for male and female pattern hair loss|
EP3749373A1|2018-02-07|2020-12-16|Regeneron Pharmaceuticals, Inc.|Methods and compositions for therapeutic protein delivery|
WO2019169330A1|2018-03-02|2019-09-06|Oncolix, Inc.|Method for treating cancers expressing prolactin receptor|
CN109627340B|2018-12-05|2021-02-12|上海交通大学|CD3 and PRLR bispecific antibody and construction and application thereof|
US10467487B1|2018-12-11|2019-11-05|Chongqing Jinkang New Energy Automobile Co., Ltd.|Fusion-based traffic light recognition for autonomous driving|
CN112425568A|2020-12-11|2021-03-02|上海市计划生育科学研究所|Method for establishing benign prostatic hyperplasia BPH dog model with EMT characteristics|
法律状态:
2018-03-06| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
2019-07-02| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
2019-09-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
2020-03-10| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|
2020-09-08| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
2020-12-29| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
2021-05-25| B16C| Correction of notification of the grant|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
优先权:
申请号 | 申请日 | 专利标题
EP09075546A|EP2332995A1|2009-12-10|2009-12-10|Neutralizing prolactin receptor antibodies and their therapeutic use|
EP09075546.3|2009-12-10|
PCT/EP2010/067742|WO2011069795A1|2009-12-10|2010-11-18|Neutralizing prolactin receptor antibodies and their therapeutic use|
[返回顶部]